

REFERENCES REVIEWED

ANTIBIOTIC PRESCRIBING PEARLS

RESISTANCE

1. Adam HJ, Hoban DJ, Gin AS, Zhanel G. Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistance *Streptococcus pneumoniae* in Canada, 1997-2006. *Int J Antimicrob Agents* 2009;34:82-85.
2. Arason VA, Kristinsson KG, Sigurdsson JA, et al. Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross-sectional prevalence study. *BMJ* 1996;313:387-91.
3. Albrich WC, Monnet D, Harbarth S. Antibiotic selection pressure and resistance in *Streptococcus pneumoniae* and *Streptococcus pyogenes*. *Emerg Infect Dis* 2004;10:514-7.
4. Bergman M, Huikko S, Pihlajamaki M, et al. Effect of macrolide consumption on erythromycin resistance in *Streptococcus pyogenes* in Finland in 1997-2001. *Clin Infect Dis* 2004;38:1251-6.
5. Butler CC et al. Variation in antibiotic prescribing and its impact on recovery in patients with acute cough in primary care: Prospective study in 13 countries. *BMJ* 2009 338:b2242.
6. Chen DK, McGeer A, de Azavedo JC et al. Decreased susceptibility of *Streptococcus pneumoniae* to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. *N Engl J Med* 1999;341:233-9.
7. (CBSN) Canadian Bacterial Surveillance Network. Department of Microbiology, Mt. Sinai Hospital and University Health Network (UHN), Toronto, ON. 2009.
<http://microbiology.mtsinai.on.ca/research/cbsn/default.asp>
8. Chen DK, McGeer A, de Azavedo JC, Low DE, for The Canadian Bacterial Surveillance Network. Decreased susceptibility of *Streptococcus pneumoniae* to fluoroquinolones in Canada. *NEJM* 1999;341(4):233-239.
9. Conly J. Antimicrobial resistance-Judicious use is the key. *CJIDMM*. 2004;15(5): 249-251.
10. Gagliotti C, Nobilio L, Milandri M, Moro ML for the Emilia-Romagna Antibiotic Resistance Study Group. Macrolide prescriptions and erythromycin resistance of *Streptococcus pyogenes*. *CID*. 2006;42:1153-1156.
11. Granzio JJ, Aguilar L, Casal J, Dal-Re, Baquero F. *Streptococcus pyogenes* resistance to erythromycin in relation to macrolide consumption in Spain (1986-1997). *J Antimicrob Chemother* 2000;46:959-64.
12. Karlowsky JA, Hoban, DJ, DeCorby MR, Laing NM, Zhanel GG. Fluoroquinolone-Resistant Urinary Isolates of *Escherichia coli* from Outpatients Are Frequently Multidrug Resistant: Results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance Study. *Antimicrobial agents and chemotherapy*. 2006;50(6):2251-54.
13. Karlowsky JA, Lagacé-Wiens PR, Low DE, Zhanel GG. Annual macrolide prescription rates and the emergence of macrolide resistance among *Streptococcus pneumoniae* in Canada from 1995 to 2005. *Int J Antimicrob Agents*. 2009 Oct;34(4):375-9.
14. Malhotra-Kumar S, Lammens C, Coenen S et al. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant strep in healthy volunteers: a randomised, double-blind, placebo-controlled study. *Lancet*. 2007;369:482.
15. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. *Clin Infect Dis* 2007;44:S27-72.
16. McGeer A, Fleming CA, Willey BM, Low DE. Antimicrobial resistance in common hospital pathogens in Ontario. 2009 QMP-LS (Quality Management Program-Laboratory Services), Ontario Medical Association, Nov. 2009;No.144:1-18.
17. Mulvey MR, Simor AE. Antimicrobial resistance in hospitals: How concerned should we be? *CMAJ* • February 17, 2009; 180 (4):408-415.
18. Ota KV, Fisman DN, Tamari IE, Smieja M et al. Incidence and treatment outcomes of pharyngeal *Neisseria gonorrhoeae* and *Chlamydia trachomatis* infections in men who have sex with men: a 13-year retrospective cohort study. *Clin Infect Dis*. 2009 May 1;48(9):1237-43.
19. Ota KV, Jamieson F, Fisman DN, Jones KE et al. Prevalence of and risk factors for quinolone-resistant *Neisseria gonorrhoeae* infection in Ontario. *CMAJ*. 2009 Feb 3;180(3):287-90.

20. Patrick DM, Hutchinson J. Antibiotic use and population ecology: How you can reduce your "resistance footprint. 2009. *CMAJ*. 2009;180(4):416-421.
21. Petersen I, Hayward AC for SACAR Surveillance Group. Antibacterial prescribing in primary care. *J Antimicrob Chemo Ther* 2007;60 Suppl 1;143-47.
22. Spurling GK, Del Mar CB, Dooley L, et al. Delayed antibiotics for respiratory infections. *Cochrane Database Syst Rev* 2007;(4):CD004417.
23. Tapsall JW, Ndowa F, Lewis DA, Unemo M. Meeting the public health challenge of multidrug- and extensively drug-resistant *Neisseria gonorrhoeae*. *Expert Rev Anti Infect Ther*. 2009 Sep;7(7):821-34.
24. Vanderkooi OG, Low DE, Green K et al. Predicting antimicrobial resistance in invasive pneumococcal infections. *CID*. 2005;40(1):1288-1296.
25. Wierzbowski AK, Taylor F, Kalowsky JA et al. Antimicrobial-resistant *Streptococcus pneumoniae* in Canadian hospitals: Results from CANWARD 2007. *Can J Infect Dis Med Microbiol*. 2009;20(Suppl. A):37A-42A.
26. Workowski KA, Berman SM, Douglas JM Jr. Emerging antimicrobial resistance in *Neisseria gonorrhoeae*: urgent need to strengthen prevention strategies. *Ann Intern Med*. 2008 Apr 15;148(8):606-13.
27. Wu HM, Harcourt BH, Hatcher CP et al. Emergence of ciprofloxacin-resistant *Neisseria meningitidis* in North America. *NEJM*. 2009;360(9):886-892.
28. Zhanel GG, DeCorby M, Nichol KA et al. Antimicrobial susceptibility of 6185 organisms isolated from Canadian hospitals: CANWARD 2007. *Can J Infect Dis Med Microbiol*. 2009;20(Suppl. A):20A-30A.

PENICILLIN-CEPHALOSPORIN CROSS ALLERGY

1. American Academy of Allergy, Asthma and Immunology. Solensky R, Banerji A, Bloomberg GR et al. Cephalosporin administration to patients with a history of penicillin allergy. 2009;pgs. 1-18. Available: aaaai.org/members/academy_statements/.../cephalosporin_paper.pdf
2. (Am Acad Ped) American Academy of Pediatrics and American Academy of Family Physicians. Subcommittee on Management of Acute Otitis Media. Clinical Practice Guideline: Diagnosis and management of acute otitis media. *Pediatrics*. 2004;113(5):1451-1465.
3. (Can Paed Soc) Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Forgie S, Zhanel G, Robinson J. Position Statement: Management of acute otitis media. *Paediatr Child Health* 2009;14:457-60.
4. Daulat SB, Solensky R, Earl HS, Casey W, Gruchalla RS. Safety of cephalosporin administration to patients with histories of penicillin allergy. *J Allergy Clin Immunol*. 2004;113:1220-1222.
5. DePestel KK, Benninger MS, Danziger L, LaPlante KL, May C, Luskin A, Pichichero M, Hadley JA. Cephalosporin use in treatment of patients with penicillin allergies. *J Am Pharm Assoc*. 2008;48:530-40.
6. Goodman EJ, Morgan MJ, Johnson PA, Nichols BA, Denk N, Gold BB. Cephalosporins can be given to penicillin-allergic patients who do not exhibit an anaphylactic response. *J Clin Anesth*. 2001;13:561-564.
7. Pennie R. Personal communication. Infectious Disease, Brantford General Hospital. January 2010.
8. Pichichero ME. A review of evidence supporting the American Academy of Pediatrics recommendation for prescribing cephalosporin antibiotics for penicillin-allergic patients. *Pediatrics*. 2005;115(4):1048-1057.

NATIONAL AND INTERNATIONAL GUIDELINES

1. Bartlett, JG (Ed.) John Hopkins Antibiotics Guide, 2009. <http://prod.hopkins-abxguide.org/>
2. Blondel-Hill E. and Fryters S. Bugs and Drugs (4th Ed.) 2006. Capital Health, Edmonton, Alberta, Canada.
3. Custer JW, Rau RE, eds. The Harriet Lane Handbook: A Manual for Pediatric House Officers/The Harriet Lane Service, Children's Medical and Surgical Center of the Johns Hopkins Hospital. 18th ed. Philadelphia, PA: Mosby, Inc; 2008.
4. eCPS online edition. Canadian Pharmacists Association. Compendium of Pharmaceutical Specialties: www-e-therapeutics.ca

5. Gilbert DN, Moellering Jr. RC, Eliopoulos GM, et al. Sanford Guide to Antimicrobial Therapy 38th Ed. Antimicrobial Therapy Inc. 2008.
6. (MQIC, 2008) Michigan Quality Improvement Consortium: Management of uncomplicated acute bronchitis in adults guideline 2008. Available from: <http://www.mqic.org/pdf/>
7. Merck Manuals Online Medical Library. Eds. Porter RS and Laplan JL. 2008. Merck Research Laboratories, Whitehouse Station, NJ, USA.
8. (NHS) National Health Services-Clinical Knowledge Summaries. (formerly Prodigy) Available at: <http://cks.library.nhs.uk/>
9. Rx Files. Jensen B, Regier LD. Drug Comparison Charts. 2008.
10. (TOP) Towards Optimal Prescribing. Alberta CPG Working Group for Antibiotics, Alberta Medical Assoc, 2008. Available from: www.cpg@topalbertadoctors.org
11. UHN (University Health Network) Guidelines for Antimicrobial Use. 2009. Toronto, Ontario.

EYE INFECTIONS

ACUTE CONJUNCTIVITIS AND BLEPHARITIS

1. (AAO, 2008) American Academy of Ophthalmology Corneal/External Disease Panel. Preferred Practice Pattern: Conjunctivitis. San Francisco, Ca: AAO; 2008. <http://one.aao.org/CE/PracticeGuidelines/>
2. (AAP) American Academy of Pediatrics- Red Book. 2006. Report of the Committee on Infectious Disease. Workowski et al. Sex. Trans. Disease, 2006. MMWR Recommen. Rep 2006; 55:1.
3. (AOA, 2002) American Optometric Association. Care of the patient with conjunctivitis. 2nd edition. St. Louis MO: American Optometric Association; 2002. Available at: <http://www.aoa.org/documents/CPG-10.pdf>
4. (AOA, 2003) American Optometric Association. Optometric Clinical Practice Guideline: Care of the patient with ocular surface disorders. 2nd edition (2003). www.aoa.org/documents/CPG-10.pdf
5. (CAN STI) Public Health Agency of Canada (PHAC). Canadian Guidelines on Sexually Transmitted Infections. Update 2008. Available at: <http://www.phac-aspc.gc.ca/>
6. Epling J. Bacterial conjunctivitis. Clin Evid 2007;pii:0704 (on-line).
7. Everitt HA, Little PS, Smith PW. A randomized controlled trial of management strategies for acute infective conjunctivitis in general practice. BMJ 2006;333:321.
8. Granet DB, Dorfman M, Stroman D, et al. A multicenter comparison of polymyxin B sulfate/trimethoprim ophthalmic solution and moxifloxacin in the speed of clinical efficacy for the treatment of bacterial conjunctivitis. J Pediatr Ophthalmol Strabismus. 2008;45:340-9.
9. Health Canada. First Nations and Inuit Health Branch Clinical Practice Guidelines for Nurses in Primary Care. 2000. Chapter 1. The Eyes. www.hc-sc.gc.ca/
10. Hovding G. Acute bacterial conjunctivitis. Acta Ophthalmol 2008;86:5-17
11. Jackson WB. Blepharitis: Current strategies for diagnosis and management. Can J Ophthalmol 2008;43:170-179.
12. Kowalski RP, Dhaliwal DK, Karenchak LM, et al. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol. 2003;136:500-505.
13. Mather R, Karenchak LM, Romanowski EQ, Kowalski RP. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol. 2002;133:463-466.
14. McCulley JP, Shine WE. Changing concepts in the diagnosis and management of blepharitis. Cornea. 2000;19:650-8.
15. Patel PB, Diaz MC, Bennett JE, et al. Clinical features of bacterial conjunctivitis in children. Acad Emerg Med. 2007 Jan;14(1):1-5.
16. Rhee DJ, Colby KA, Rapuano CJ, Sobrin L. Ophthalmologic Drug Guide. 2007. Springer Science and Business Media, LLC, NY, USA.
17. Rietveld RP, ter Riet G, Bindels PJ et al. Do general practitioners adhere to the guideline on infectious conjunctivitis? Results of the Second Dutch National Survey of general practice. BMC Fam Pract 2007;8:54.
18. Rietveld RP, ter Riet G, Bindels PJ. Predicting bacterial cause in infectious conjunctivitis: cohort study on informativeness of combinations of signs and symptoms. BMJ 2004; 329:206-210.
19. Rietveld RP, ter Riet G, Bindels PJ et al. The treatment of acute infectious conjunctivitis with fusidic acid: A randomised controlled trial. Br J Gen Pract 2005; 55(521):924-30.

20. Rietveld RP, van Weert HC, ter Riet G. Diagnostic impact of signs and symptoms in acute infectious conjunctivitis: systematic literature search. *BMJ* 2003; 327:789.
21. Sheikh A, Hurwitz B. Antibiotics versus placebo for acute bacterial conjunctivitis. (Cochrane Review). In: *The Cochrane Library*, Issue 3, 2009.
22. Sheikh Z, Hurwitz B. Topical antibiotics for acute bacterial conjunctivitis: Cochrane systematic review and meta-analysis update. *Br J General Prac* 2005;55:962-4.
23. Silver LH, Woodside AM, Montgomery DB. Clinical safety of moxifloxacin ophthalmic solution 0.5% (Vigamox) in pediatric and nonpediatric patients with bacterial conjunctivitis. *Surv Ophthalmol.* 2005;50 Suppl 1:S55-63.
24. Tarabishy AB, Jeng BH. Bacterial conjunctivitis: a review for internists. *Cleve Clin J Med.* 2008 ;75:507-12.
25. Visscher KL, Hutnik CML, Thomas M. Evidence-based treatment of acute infective conjunctivitis. Breaking the cycle of antibiotic prescribing. *Can Fam Physician* 2009;55:1071-5.

RESPIRATORY

PHARYNGITIS

1. Adam D, Scholz H. Five days of erythromycin estolate versus ten days of penicillin V in the treatment of group A streptococcal tonsillopharyngitis in children. *Pharyngitis Study Group. Eur J Clin Microbiol Infect Dis* 1996;15(9):712-7.
2. AHA (American Heart Association). Gerber M, Baltimore R, Eaton C, et al. Prevention of rheumatic fever and diagnosis and treatment of acute streptococcal pharyngitis. A scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease. *Circulation* 2009;119:1541 – 1551.
3. Alcaide ML, Bisno AL. Pharyngitis and epiglottitis. *Infect Dis Clin North Am* 2007;21:449-69, vii.
4. Altamimi S, Khalil A, Khalaiwi KA, et al. Short versus standard duration antibiotic therapy for acute streptococcal pharyngitis in children. (Cochrane Review). In: *The Cochrane Library*, Issue 1, 2009.
5. Bisno, AL. Are cephalosporins superior to penicillin for treatment of acute streptococcal pharyngitis? *Clin Infect Dis* 2004;38:1535-7.
6. Brook I, Dohar JE. Management of group A -hemolytic Streptococcal pharyngotonsillitis in children. *J Fam Pract* 2006; 55(12):S1-11.
7. Casey JR, Pichichero ME(a). The evidence base for cephalosporin superiority over penicillin in streptococcal pharyngitis. *Diagn Microbiol Infect Dis.* 2007;57(3 Suppl):39S-45S.
8. Casey JR, Pichichero ME. Meta-analysis of cephalosporins versus penicillin for treatment of Group A Streptococcal tonsillopharyngitis in adults. *Clin Infect Disease* 2004;38:1526-34.
9. Casey JR, Pichichero ME(a). Meta-analysis of short course antibiotic treatment for group a streptococcal tonsillopharyngitis. *Pediatr Infect Dis J.* 2005;24(10):909-17.
10. Casey JR, Pichichero ME(b). Higher dosages of azithromycin are more effective in treatment of Group A Streptococcal tonsillopharyngitis. *Clin Infect Dis* 2005;14:1748-55.
11. Casey JR, Pichichero ME(b). Symptomatic relapse of group A beta-hemolytic streptococcal tonsillopharyngitis in children. *Clin Pediatr* 2007;46:307-10.
12. Centor RM. Expand the Pharyngitis Paradigm for Adolescents and Young Adults. *Annals of Internal Medicine.* 2009;151(11): 812-815.
13. Centor RM(a), Allison JJ, Cohen SJ. Pharyngitis management: defining the controversy. *J Gen Intern Med* 2007;33:127-30.
14. Centor RM(b), Mobin S, Chester W. It's 5 pm Friday; the caller thinks he has strep – Do you write that script? *J Fam Pract* 2007;56:922-4.
15. Cohen R(a), Levy C, Ovetchkine P et al. Evaluation of Streptococcal clinical scores, rapid antigen detection tests and cultures for childhood pharyngitis. *Eur J Pediatr* 2004;163:281-2.
16. Cohen R(b). Defining the optimum treatment regimen for azithromycin in acute tonsillopharyngitis. *Pediatr Infect Dis J* 2004;23(2 Suppl):S129-34.
17. Corneli HM. Rapid detection and diagnosis of group A Streptococcal pharyngitis. *Curr Infect Dis Rep* 2004; 6(3):181-6.
18. DePestel KK, Benninger MS, Danziger L, LaPlante KL, May C, Luskin A, Pichichero M, Hadley JA. Cephalosporin use in treatment of patients with penicillin allergies. *J Am Pharm Assoc.* 2008;48:530-40.

19. Forward KR, Haldane D, Webster D. A comparison between the Strep A rapid test device and conventional culture for the diagnosis of streptococcal pharyngitis. *Can J Infect Dis Med Microbiol* 2006;17:221-3.
20. Gerber MA. Diagnosis and treatment of pharyngitis in children. *Pediatr Clin N Am* 2005;52:729-47.
21. Karkos PD, Asrani S, Karkos CD, et al. Lemierre's syndrome: A systematic review. *Laryngoscope* 2009;119:1552-59.
22. Madden S, Kelly L. Update on acute rheumatic fever. *Can Fam Physician* 2009;55:475-8.
23. Maltezou HC, Tsagris V, Antoniadou A, et al. Evaluation of a rapid antigen detection test in the diagnosis of streptococcal pharyngitis in children and its impact on antibiotic prescription. *J Antimicrob Chemother* 2008;62:1407-12.
24. (MQIC, 2008) Michigan Quality Improvement Consortium: Management of Uncomplicated Acute Bronchitis in Adults Guideline 2008. Available from: <http://www.mqic.org>
25. Milatovic D. Evaluation of cefadroxil, penicillin and erythromycin in the treatment of streptococcal tonsillopharyngitis. *Pediatr Infect Dis J* 1991;10(10 Suppl):S61-3.
26. McCarty J, Hedrick J, Gooch W. Clarithromycin suspension versus penicillin V suspension in children with streptococcal pharyngitis. *Adv Ther* 2000;17:14-26.
27. (NICE, 2008) National Institute for Health and Clinical Excellence. Respiratory tract infections – antibiotic prescribing. Prescribing of antibiotics for self-limiting respiratory tract infections in adults and children in primary care 2008. Available from: <http://www.nice.org.uk/CG069>
28. Pichichero M, Casey J. Comparison of European and U.S. results for cephalosporin versus penicillin treatment of group A streptococcal tonsillopharyngitis. *Eur J Clin Microbiol Infect Dis*. 2006;25(6):354-64.
29. Pichichero ME, Casey JR. Bacterial eradication rates with shortened courses of 2nd- and 3rd-generation cephalosporins versus 10 days of penicillin for treatment of group A streptococcal tonsillopharyngitis in adults. *Diagn Microbiol Infect Dis*. 2007;59:127-30.
30. Pichichero ME, Casey JR, Mayes T, Francis AB, Marsocci SM, Murphy AM, Hoeger W. Penicillin failure in streptococcal tonsillopharyngitis: causes and remedies. *Pediatr Infect Dis J*. 2000;19:917-23.
31. Shah M, Centor RM, Jennings M. Severe acute pharyngitis caused by group C streptococcus. *J Gen Intern Med*. 2007;22:272-4.
32. Skolnik, NS. *Essential Practice Guidelines in Primary Care*. Totowa, New Jersey: Humana Press; 2007.
33. Syrogiannopoulos G. Two dosages of clarithromycin for five days, amoxicillin/ clavulanate for five days or penicillin V for ten days in acute group A streptococcal tonsillopharyngitis. *Pediatr Infect Dis J* 2004;23:857–65.
34. Worrall G, Hutchinson J, Sherman G, et al. Diagnosing streptococcal sore throat in adults: randomized controlled trial of in-office aids. *Can Fam Physician* 2007;53:667-71, 666.
35. Zwart S, Rovers MM, de Melker RA, et al. Penicillin for acute sore throat in children: Randomised, double blind trial. *BMJ* 2003;327:1324.

EPIGLOTTIS

1. Alcaide ML, Bisno AL. Pharyngitis and epiglottitis. *Infect Dis Clin North Am* 2007;21:449-69, vii.
2. Burns, J.E. and Hendley, J.O. (2005) Epiglottitis. In: Mandell, G.L., Bennett, J.E. and Dolin, R. (Eds.) *Mandell, Douglas, and Bennett's principles and practice of infectious diseases*. 6th edn. Philadelphia: Elsevier Churchill Livingstone.
3. Hafidh MA, Sheahan P, Keogh I, et al. Acute epiglottitis in adults: a recent experience with 10 cases. *J Laryngol Otol* 2006; 120:310-3.
4. Katori H, Tsukuda M. Acute epiglottitis: analysis of factors associated with airway intervention. *J Laryngol Otol* 2005;119:967-972.
5. (NHS) National Health Services Clinical Knowledge Summaries. Sore throat - acute - Making a diagnosis Epiglottitis. Available at: <http://cks.library.nhs.uk/>.
6. Sobol SE, Zapata, S. Epiglottitis and croup. *Otolaryngol Clin N Am* 2008;41:551-566.

LARYNGITIS AND CROUP

1. Ausejo M, Saenz A, Pham B, et al. The effectiveness of glucocorticoids in treating croup: meta-analysis. *West J Med* 1999;171:227-32.
2. Guppy MPB, Mickan SM, Del Mar C. Advising patients to increase fluid intake for treating acute respiratory infections. (Cochrane Review). In: *The Library*, Issue 4, 2005.

3. Klassen TP et al. Nebulized budesonide and oral dexamethasone for treatment of croup: a randomized controlled trial. *JAMA* 1998;279:1629-32.
4. Moore M, Little P. Humidified air inhalation for treating croup: a systematic review and meta-analysis. *Fam Pract* 2007;24:295-301.
5. (NHS) National Health Services Clinical Knowledge Summaries. Sore throat – acute – Laryngitis. Available at: <http://cks.library.nhs.uk/>
6. Reveiz L, Cardona AF, Ospina EG. Antibiotics for acute laryngitis in adults. (Cochrane Review). In: The Cochrane Library, Issue 2, 2007.
7. Sobol SE, Zapata S. Epiglottitis and croup. *Otolaryngol Clin N Am* 2008;41:551-566.

ACUTE RHINITIS

1. Arroll B, Kenealy T. Antibiotics for the common cold and acute purulent rhinitis. (Cochrane Review). In: The Cochrane Library, Issue 2, 2005.
2. Basco WT. Potential Dangers of Cough and Cold Medications in Children. (2009) Available at: <http://www.medscape.com/viewarticle/586718>
3. Caruso TJ, Prober CG, Gwaltney JM Jr. Treatment of naturally acquired common colds with zinc: a structured review. *Clin Inf Dis* 2007;45:569.
4. Health Canada Advisory - Decision on the Labelling of Cough and Cold Products for Children. Health Canada. December 2008.
5. Hemilä H, Chalker E, Treacy B, et al. Vitamin C for preventing and treating the common cold. (Cochrane Review). In: The Cochrane Library, Issue 3, 2007.
6. (ICSI, 2008) Institute for Clinical Systems Improvement. Diagnosis and treatment of respiratory illness in children and adults 2008 (2nd edition). Available from: www.icsi.org
7. Latte GJ. Nasal decongestants for the common cold. (Cochrane Review). In: The Cochrane Library, Issue 1, 2007.
8. Linde K, Barrett B, Bauer R, et al. Echinacea for preventing and treating the common cold. (Cochrane Review). In: The Cochrane Library, Issue 1, 2006.
9. (NICE, 2008) National Institute for Health and Clinical Excellence. Respiratory tract infections – antibiotic prescribing. Prescribing of antibiotics for self-limiting respiratory tract infections in adults and children in primary care 2008. Available from: <http://www.nice.org.uk/CG069>
10. Taverner D, Latte GJ. Nasal decongestants for the common cold. (Cochrane Review). In: The Cochrane Library, Issue 1, 2007.
11. Timmer A, Günther J, Rücker G, et al. Pelargonium sidoides extract for acute respiratory tract infections. (Cochrane Review). In: The Cochrane Library, Issue 3, 2008.
12. Wu T, Zhang J, Yan Q, et al. Chinese medicinal herbs for the common cold. (Cochrane Review). In: The Cochrane Library, Issue 1, 2007.

INFLUENZA

1. Allen UD, Aoki F, Stiver HG et al. The use of antiviral drugs for influenza: Recommended guidelines for practitioners. *Can J Infect Dis Med Microbiol* 2006;17:273-79.
2. Alves GMG, Rocha Crispino Santos MA, Alves da Cunha AJL. Amantadine and rimantadine for influenza A in children and the elderly. (Cochrane Review). In: The Cochrane Library, Issue 1, 2008.
3. (CCDR, 2008) Health Canada. Public Health Agency of Canada. Flu Watch. Available: http://www.phac-aspc.gc.ca/fluwatch/08-09/w01_09/index-eng.php
4. (CDC, 2009/10) Centers for Diseases Control and Prevention. Recommended Daily Dosage of Seasonal Influenza Antiviral Medications for Treatment and Chemoprophylaxis for the 2009-10 Season—United States. Available: <http://www.cdc.gov>.
5. Canadian Paediatric Society. The use of antiviral drugs for influenza: Recommended guidelines for practitioners. *Paediatr Child Health* 2006;11:520.
6. CPS 2010. Compendium of Pharmaceuticals and Specialties. Canadian Pharmacists Association.
7. Chen X, Wu T, Liu G, et al. Chinese medicinal herbs for influenza. (Cochrane Review). In: The Cochrane Library, Issue 4, 2007.

8. (CID) Committee on Infectious Diseases. Antiviral therapy and prophylaxis for influenza in children. *Pediatrics*. 2007 Apr;119:852-60.
9. Demicheli V, Rivetti D, Deeks JJ, Jefferson TO. Vaccines for preventing influenza in health adults. *Cochrane Database Syst Rev*. 2004;(3):CD001269.
10. Deonandan R, Mensinkai S, Hodgson A. Effectiveness of neuraminidase inhibitors for prevention of influenza [Technology Report number 79]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2007.
11. Fiore AE, Shay DK, Haber P, et al. Prevention and control of influenza: Recommendations of the advisory committee on immunization practices (ACIP) 2008. *MMWR* 2008; 56 (Early Release);1-54.
12. Galvão MGA, Santos MARC, da Cunha AJLA. Amantadine and rimantadine for influenza A in children and the elderly. (Cochrane Review). In: *The Cochrane Library*, Issue 1, 2008.
13. Harper SA, Bradley JS, Englund JA, et al. Seasonal Influenza in Adults and Children—Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management: Clinical Practice Guidelines of the Infectious Diseases Society of America. *CID* 2009;48:1003-32.
14. Hayden FG, Belshe R, Villanueva C, et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. *J Infect Dis* 2004;189:440-9.
15. Jefferson T, Del Mar C, Dooley L et al. Physical interventions to reduce the spread of respiratory viruses. *BMJ* 2009;339 :b3675.
16. Jefferson T, Demicheli V, Di Pietrantonj C, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults. (Cochrane Review). In: *The Cochrane Library*, Issue 3, 2006.
17. Jefferson T, Rivetti A, Harnden A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in health children. 2008;2:CD004879.
18. Matheson NJ, Harnden A, Perera R, Sheikh A, Symmonds-Abrahams M. Neuraminidase inhibitors for preventing and treating influenza in children. *Cochrane Database of Systematic Reviews* 2007, Issue 1. Art. No.: CD002744.
19. The Medical Letter Inc. Antiviral drugs for influenza. *Med Lett* 2008;50:98.
20. (NACI, 2008) National Advisory Committee on Immunization. Statement on Influenza Vaccination for the 2008-2009 season. Available at: <http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/08pdf/acs-3.pdf>
21. (NICE, 2008) National Institute for Health and Clinical Excellence. Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza. NICE technology appraisal guidance 158. Available: <http://www.nice.org.uk/Guidance/TA158/Guidance/pdf/English>
22. (PHAC, 2009) Public Health Agency of Canada. National influenza treatment guidelines: interim options for clinicians considering influenza antivirals in the context of changing patterns of resistance, 2009-10 season. Available from: <http://www.phac-aspc.gc.ca>
23. Piedra PA, Schulman KL, Blumentals WA. Effects of oseltamivir on influenza-related complications in children with chronic medical conditions. *Pediatrics*. 2009 Jul;124:170-8
24. Shun-Shin M, Thompson M, Heneghan C et al. Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta-analysis of randomized controlled trials. *BMJ* 2009;339:b3172doi:10.1136/bmj.b3172
25. Tanaka T, Nakajima K, Murashima A. et al. Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women. *CMAJ* 2009. 181(1-2):55-8.
26. Vickers A, Smith C. Homoeopathic Oscillocoquinum for preventing and treating influenza and influenza-like syndromes. (Cochrane Review). In: *The Cochrane Library*, Issue 3, 2006.
27. Welliver R, Gubareva LV, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. *JAMA* 2001;285:748-54.

OTITIS EXTERNA AND OTITIS MEDIA

1. (Am Acad Peds, 2006) American Academy of Pediatrics Committee on Infectious Diseases. The use of systemic fluoroquinolones. *Pediatrics* 2006 ;118:1287-92.
2. (Am Acad Ped) American Academy of Pediatrics and American Academy of Family Physicians. Subcommittee on Management of Acute Otitis Media. Clinical Practice Guideline: Diagnosis and management of acute otitis media. *Pediatrics*. 2004;113(5):1451-1465.
3. (Can Paed Soc) Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Forgie S, Zhanel G, Robinson J. Position Statement: Management of acute otitis media. *Paediatr Child Health* 2009;14:457-60.

4. Christian-Kopp S, Sinha M, Rosenberg DI, Eisenhart AW, McDonald FW Antibiotic dosing for acute otitis media in children: a weighty issue. *Pediatr Emerg Care*. 2010 Jan;26(1):19-25.
5. Custer JW, Rau RE, eds. *The Harriet Lane Handbook: A Manual for Pediatric House Officers/The Harriet Lane Service, Children's Medical and Surgical Center of the Johns Hopkins Hospital*. 18th ed. Philadelphia, PA: Mosby, Inc; 2008.
6. Dohar JE, Alper CM, Rose EA et al. Treatment of CSOM with topical ciprofloxacin. *Am Otol Rhinol Laryngol* 1998;107:865-71.
7. Drehobl M, Guerrero JL, Lacarte PR, et al. Comparison of efficacy and safety of ciprofloxacin otic solution 0.2% versus polymyxin B-neomycin-hydrocortisone in the treatment of acute diffuse otitis externa. *Curr Med Res Opin* 2008;24:3531-42.
8. Foxlee R, Johansson A, Weifalk J, et al. Topical Analgesia for Acute Otitis Media. (Cochrane Review). In: *The Cochrane Library*, Issue 3, 2006.
9. Garry JP; Otitis externa. *eMedicine*, November 2007.
10. Griffin GH, Flynn C, Bailey R, et al. Antihistamines and/or decongestants for otitis media with effusion (OME) in children. (Cochrane Review). In: *The Cochrane Library*, Issue 4, 2006.
11. Ho T, Vrabec JT, Yoo D, Coker NJ. Otomycosis: clinical features and treatment implications. *Otolaryngol Head Neck Surg* 2006;135:787-791.
12. Jackman A, Ward R, April M, Bent J. Topical antibiotic induced otomycosis. *Int J Pediatr Otorhinolaryngol*. 2005;69:857-860.
13. Leach AJ, Morris PS. Antibiotics for the prevention of acute and chronic suppurative otitis media in children. (Cochrane Review). In: *The Cochrane Library*, Issue 4, 2006.
14. Le Saux N, Gaboury I, Baird M, et al. A randomized double-blind, placebo-controlled non-inferiority trial of amoxicillin for clinically diagnosed acute otitis media in children 6 months to 5 years of age. *CMAJ* 2005;172:335-41.
15. Levenson MJ, Parisier SC, Dolitsky J, Bindra G. Ciprofloxacin: drug of choice in the treatment of malignant external otitis (MEO). *Laryngoscope* 1991;101:821-824.
16. McCormick DP, Chonmaitree T, Pittman C, Saeed K, Friedman NR, Uchida T, Baldwin CD. Nonsevere acute otitis media: a clinical trial comparing outcomes of watchful waiting versus immediate antibiotic treatment. *Pediatrics*. 2005 Jun;115(6):1455-65.
17. Munguia R, Daniel SJ. Otological antifungals and otomycosis: A review. *Int J of Ped Otorhinolaryngology*. 2008; 72:453-459.
18. Pappas DE, Owen Hendley J; Otitis media. A scholarly review of the evidence. *Minerva Pediatr*. 2003; Oct;55(5):407-14.
19. Paradise JL, Campbell TF, Dollaghan CA, et al. Developmental outcomes after early or delayed insertion of tympanostomy tubes. *N Engl J Med* 2005;353:576-86.
20. Pichichero ME. A review of evidence supporting the American Academy of Pediatrics recommendation for prescribing cephalosporin antibiotics for penicillin-allergic patients. *Pediatrics*. 2005;115(4):1048-1057.
21. Pichichero ME, Casey JR. Diagnostic inaccuracy and subject exclusions render placebo and observational studies of acute otitis media inconclusive. *Pediatr Infect Dis J*. 2008 Nov;27(11):958-62.
22. Rahman A, Rizwan S, Waycaster C, Wall GM. Pooled analysis of two clinical trials comparing the clinical outcomes of topical ciprofloxacin/dexamethasone otic suspension and polymyxin B/neomycin/hydrocortisone otic suspension for the treatment of acute otitis externa in adults and children. *Clin Ther*. 2007;29(9):1950-6.
23. Roland PS, Belcher BP, Bettis R, Makabale RL, Conroy PJ, Wall GM, Dupre S, Potts S, Hogg G, Weber K; Cipro HC Study Group. A single topical agent is clinically equivalent to the combination of topical and oral antibiotic treatment for otitis externa. *Am J Otolaryngol*. 2008 Jul-Aug;29(4):255-61.
24. Rosenfeld RM, Brown L, Cannon CR, et al. American Academy of Otolaryngology--Head and Neck Surgery Foundation. Clinical practice guideline: acute otitis externa. *Otolaryngol Head Neck Surg* 2006;134(4 Suppl):S4-23
25. Rovers MM, Glasziou P, Appelman CL, et al. Antibiotics for acute otitis media: a meta-analysis with individual patient data. *Lancet*. 2006 Oct 21;368(9545):1429-35.
26. Rovers MM, Glasziou P, Appelman CL et al. Predictors of pain and/or fever at 3 to 7 days for children with acute otitis media not treated initially with antibiotics: a meta-analysis of individual patient data. *Pediatrics* 2007;119(3):579-85.
27. Schwartz RH. Once-daily ofloxacin otic solution versus neomycin sulfate/polymyxin B sulfate/hydrocortisone otic suspension four times a day: a multicenter, randomized, evaluator-blinded trial to compare the efficacy, safety, and pain relief in pediatric patients with otitis externa. *Curr Med Res Opin*. 2006;22(9):1725-36.

28. Spiro DM, Tay KY, Arnold DH, et al. Wait-and-see prescription for the treatment of acute otitis media: a randomized control trial. *JAMA* 2006;296:1235-41.
29. Tan T, Little P, Stokes T, et al. Antibiotic prescribing for self limiting respiratory tract infections in primary care: summary of NICE guidance. *BMJ* 2008;337:a437.
30. Vernacchio L, Vezina RM, Mitchell AA. Management of acute otitis media by primary care physicians: trends since the release of the 2004 American Academy of Pediatrics/American Academy of Family Physicians clinical practice guideline. *Pediatrics* 2007;120:281-7.
31. Wall GM, Stroman DW, Roland PS, Dohar J. Ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension for the topical treatment of ear infections: a review of the literature. *Pediatr Infect Dis J.* 2009 Feb;28(2):141-4.

SINUSITIS

1. Ahovuo-Saloranta A, Borisenko OV, Kovanen N, et al. Antibiotics for acute maxillary sinusitis (Cochrane Review). In: *The Cochrane Library*, Issue 2, 2008.
2. Arroll B. Antibiotics for upper respiratory tract infections: an overview of Cochrane reviews. *Respir Med* 2005;99:255-261.
3. Benninger MS, Desrosiers M, Klossek JM et al. Management of acute bacterial rhinosinusitis: current issues and future perspectives. *Int J Clin Pract* 2006;60:190-200.
4. (Can Paed Soc) Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Forgie S, Zhanel G, Robinson J. Position Statement: Management of acute otitis media. *Paediatr Child Health* 2009;14:457-60.
5. Falagas ME, Giannopoulou KP, Vardakas KZ. Comparison of antibiotics with placebo for treatment of acute sinusitis: a meta-analysis of randomised control trials. *Lancet Infect Dis* 2008;8:543-52.
6. Harvey R, Hannan SA, Badia L, et al. Nasal saline irrigations for the symptoms of chronic rhinosinusitis. (Cochrane Review). In: *The Cochrane Library*, Issue 3, 2007.
7. Karageorgopoulos DE, Giannopoulou KP, Grammatikos AP, et al. Fluoroquinolones compared with beta-lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trials. *CMAJ* 2008;178:845-54.
8. Klossek JM, Federspil P. Update on treatment guidelines for acute bacterial sinusitis. *Int J Clin Pract* 2005;59:230-8.
9. Lindbaek M, Butler CC. Antibiotics for sinusitis-like symptoms in primary care. *The Lancet* 2008;371:874-6.
10. Lusk R. Pediatric chronic sinusitis. *Curr Opin Otolaryngol Head Neck Surg* 2006;14:393-6.
11. Marple BF, Brunton S, Ferguson BJ. Acute bacterial rhinosinusitis: a review of US treatment guidelines. *Otolaryngol Head Neck Surg* 2006;135:341-8.
12. Morris P, Leach A. Antibiotics for persistent nasal discharge (rhinosinusitis) in children. (Cochrane Review). In: *The Cochrane Library*, Issue 4, 2002.
13. Musher D, Gross R, Anon J et al. Sinusitis. *N Engl J Med* 2005;352:203-4.
14. Piccirillo JF. Clinical practice. Acute bacterial sinusitis. *N Engl J Med* 2004;351:902-10.
15. Pichichero ME, Doern GV, Kufi JL et al. Probability of Achieving Requisite Pharmacodynamic Exposure for Oral beta-Lactam Regimens against *Haemophilus influenzae* in Children. *Paediatr Drugs* 2008;10:391-7.
16. Ramadan HH. Pediatric sinusitis: Update. *J Otolaryngol* 2005;34 Suppl 1:S14-7.
17. Randall DA. Re: Acute bacterial rhinosinusitis – a review of US treatment guidelines. *Otolaryngol Head Neck Surg* 2007;136(4):681; discussion 682.
18. Rosenfeld RM, Andes D, Bhattacharyya N et al. Clinical Practice Guidelines: Adult sinusitis. *Otolaryngol Head Neck Surg* 2007;137(3 Suppl):S1-31.
19. Scheid DC, Hamm RM. Evaluation of suspected acute bacterial rhinosinusitis in adults: part I. *Am Fam Physician* 2004;70:1685-92.
20. Scheid DC, Hamm RM. Evaluation of suspected acute bacterial rhinosinusitis in adults: part II. *Am Fam Physician* 2004;70:1697-704, 1711-12.
21. Steele RW. Chronic Sinusitis in Children. *Clinical Pediatrics* 2005;44:465-471.
22. Williamson IG, Rumsby K, Bengt S, et al. Antibiotics and topical nasal steroid for treatment of acute maxillary sinusitis: a randomized controlled trial. *JAMA* 2007;298:2487-96.
23. Wright ED, Frenkiel S. Infectious adult rhinosinusitis: Etiology, diagnosis, and management principles. *J Otolaryngology* 2006;34 Suppl 1:S7-13.
24. Young J, De Sutter A, Merenstein D, et al. Antibiotics for adults with clinically diagnosed acute rhinosinusitis: a meta-analysis of individual patient data. *Lancet* 2008; 371:908-14.

25. Zlamanovici A, Yaphe J. Steroids for acute sinusitis (Cochrane Review). In: The Cochrane Library, Issue 2, 2008.

ACUTE BRONCHITIS AND ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS (AECB)/ AECOPD

- 1) Altiner A, Wilm S, Däubener W, et al. Sputum colour for diagnosis of a bacterial infection in patients with acute cough. *Scand J Prim Health Care* 2009;27:70-3.
- 2) Allegra L, Bias F, Diano PL, et al. Sputum color as a marker of acute bacterial exacerbations of chronic obstructive pulmonary disease. *Respir Med* 2005;99:742-7.
- 3) Attila A, Wilm S, Daubener W et al. Sputum colour for diagnosis of a bacterial infection in patients with acute cough. *Scan J of Prim Health Care*. 2009; 27: 70-73.
- 4) Braman S. Chronic cough due to acute bronchitis: ACCP evidence-based clinical practice guidelines. *Chest* 2006;129:95-115.
- 5) Butler CC et al. Variation in antibiotic prescribing and its impact on recovery in patients with acute cough in primary care: Prospective study in 13 countries. *BMJ* 2009;338:b2242.
- 6) Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. *N Engl J Med*. 2007;356(8):775-89.
- 7) Dicipinigitis PV, Currently available antitussives. *Pulmonary Pharmacology & Therapeutics* 2009;22:148-151.
- 8) El Moussaoui R, Roede BM, Speelman P, et al. Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies. *Thorax* 2008;63:415-22.
- 9) Falagas ME, Avgeri SG, Mathaiou DK, et al. Short-versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis and COPD: a meta-analysis. *J Antimicrob Chemother* 2008;62:442-50.
- 10) (GOLD, 2008) Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management, and prevention of COPD, Updated 2008. Available from: www.goldcopd.com
- 11) (ICSI, 2009) Institute for Clinical Systems Improvement. Diagnosis and management of Chronic Obstructive Pulmonary Disease (COPD) 2009 (7th edition). Available from: www.icsi.org
- 12) (MQIC, 2008) Michigan Quality Improvement Consortium: Management of uncomplicated acute bronchitis in adults guideline 2008. Available from: <http://www.mqic.org/pdf/>
- 13) Martinez FJ, Anzueto A. Appropriate outpatient treatment of acute bacterial exacerbations of chronic bronchitis. *Am J Med* 2005;118(7A):39S-44S.
- 14) O'Donnell SE, Hernandez P, Kaplan A, et al. Canadian Thoracic Society recommendations for management of chronic pulmonary obstructive disease-2008 update-highlights for primary care. *Can Respir J* 2008;15(Suppl A):1A-8A.
- 15) Poole P, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. (Cochrane Review). In: The Cochrane Library, Issue 3, 2006.
- 16) Sethi S, et al. *Ann Clin Microbiol Antimicrob*. 2005; 4:5.
- 17) Ram FS, Rodriguez-Roisin R, Granados-Navarrete A, et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. (Cochrane Review). In: The Cochrane Library, Issue 2, 2006.
- 18) Respiratory Review Panel. Respiratory (Asthma and COPD) Guidelines for Family Practice. Toronto: MUMS Guidelines Clearinghouse; 2007.
- 19) (SIGN, 2002) Scottish Intercollegiate Guidelines Network. Community Management of Lower Respiratory Tract Infections in Adults 2002. Available from: <http://www.sign.ac.uk/pdf/sign59.pdf>
- 20) Shields MD, Bush A, Everard ML, et al. Recommendations for the assessment and management of cough in children. *Thorax* 2008; 63(Suppl III):iii1-iii15.
- 21) Stockley RA, O'Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. *Chest*. 2000;117:1638-45.
- 22) Tashkin DP, Celli B, Senn S et al. A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease. *N Engl J Med* 2008;359: 1543-54
- 23) Wilson R. Short course of antibiotic treatment in acute exacerbations of COPD. *Thorax* 2008;63:390-2.
- 24) Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. *Eur Respir J* 2005;26:1138-80.

BRONCHIECTASIS

- 1) Barker AF. Bronchiectasis. *N Engl J Med* 2002;346:1383-93.

- 2) King P. Is there a role for inhaled corticosteroids and macrolide therapy in bronchiectasis? *Drugs* 2007;67:965-74.
- 3) Rosen MJ. Chronic cough due to bronchiectasis: ACCP evidence-based clinical practice guidelines. *Chest* 2006;129:122-31.
- 4) ten Hacken NHT, Wijkstra PJ, Kerstjens HAM. Treatment of bronchiectasis in adults. *BMJ* 2007; 335:1089-93.
- 5) Tsang KW, Chan WM, Ho PL, Chan K, Lam WK, Ip MS. A comparative study on the efficacy of levofloxacin and ceftazidime in acute exacerbation of bronchiectasis. *Eur Respir J* 1999;14:1206-9.

PNEUMONIA

- 1) Adam HJ, Hoban DJ, Gin AS, Zhanel G. Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistance *Streptococcus pneumoniae* in Canada, 1997-2006. *Int J Antimicrob Agents* 2009;34:82-85.
- 2) Armitage K, Woodhead M. New guidelines for the management of adult community-acquired pneumonia. *Curr Opin Infect Dis* 2007;20:170-6.
- 3) Arnold FW, Summergill JT, Lajoie AS et al. A worldwide perspective of atypical pathogens in community-acquired pneumonia. *Am J Respir Crit Care Med* 2007;175:1086-93.
- 4) Bonfiglio G. Is levofloxacin as active as ciprofloxacin against *Pseudomonas aeruginosa*? *Chemotherapy*. 2001;47:239-242.
- 5) (CBSN) Canadian Bacterial Surveillance Network. Department of Microbiology, Mt. Sinai Hospital and University Health Network (UHN), Toronto, ON. 2009.
<http://microbiology.mtsinai.on.ca/research/cbsn/default.asp>
- 6) Chen DK, McGeer A, de Azavedo JC, Low DE, for The Canadian Bacterial Surveillance Network. Decreased susceptibility of *Streptococcus pneumoniae* to fluoroquinolones in Canada. *NEJM* 1999;341(4):233-239.
- 7) Craven DE. ATS/IDSA Hospital-acquired pneumonia guidelines: new principles for improving management. *Am J Respir Crit Care Med* 2005;171:388-416.
- 8) Daneman N, McGeer A, Green K et al. Macrolide resistance in bacteremic pneumococcal disease: Implications for patient management. *Clin Infect Dis* 2006;43:432-8.
- 9) Daneman N, Low DE, McGeer A et al. At the threshold: defining clinically meaningful resistance thresholds for antibiotic choice in community-acquired pneumonia. *Clin Infect Dis* 2008;46:1131-8.
- 10) File TM. The science of selecting antimicrobials for community-acquired pneumonia (CAP). *J Manag Care Pharm*. 2009 Mar;15(2 Suppl):S5-11.
- 11) Grant GB, Campbell H, Dowell SF, et al. Recommendations for treatment of childhood non-severe pneumonia. *Lancet* 2009;9:185-96.
- 12) (ICSI, 2006) Institute for Clinical Systems Improvement. Health care guideline: community-acquired pneumonia in adults. Available from: <http://www.icsi.org/>
- 13) Karlowky JA, Lagacé-Wiens PR, Low DE, Zhanel GG. Annual macrolide prescription rates and the emergence of macrolide resistance among *Streptococcus pneumoniae* in Canada from 1995 to 2005. *Int J Antimicrob Agents*. 2009 Oct;34(4):375-9.
- 14) Li JZ, Winston LG, Moore DH, et al. Efficacy of Short-Course Antibiotic Regimens for Community-Acquired Pneumonia: A Meta-analysis. *Am J Med* 2007;120:783-90.
- 15) Lim W, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. *Thorax*. 2003;58:377-82.
- 16) Low DE. Treatment of community-acquired pneumonia. *CMAJ* 2008;179:1245-6.
- 17) Malhotra-Kumar S, Lammens C, Coenen S et al. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant strep in healthy volunteers: a randomised, double-blind, placebo-controlled study. *Lancet*. 2007;369:482.
- 18) Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. *Clin Infect Dis* 2007;44:S27-72.
- 19) McCusker ME, Harris AD, Perencevich E, et al. Fluoroquinolone Use and *Clostridium difficile*-associated Diarrhea. *Emerg Infect Dis* 2003;9:730-3.
- 20) Mills K, Graham AC, Winslow BT, Springer KL Treatment of nursing home-acquired pneumonia. *Am Fam Physician*. 2009 Jun 1;79(11):976-82.
- 21) Owens RC Jr, Donskey CJ, Gaynes RP, et al. Antimicrobial-associated risk factors for *Clostridium difficile* infection. *Clin Infect Dis* 2008;46:S19-31.

- 22) Paris R, Confalonieri M, Dal Negro R et al. Efficacy and safety of azithromycin 1 g once daily for 3 days in the treatment of community-acquired pneumonia: an open-label randomised comparison with amoxicillin-clavulanate 875/125 mg twice daily for 7 days. *J Chemother.* 2008 Feb;20(1):77-86.
- 23) Powell KR, Baltimore RS, Bernstein H. The use of systemic fluoroquinolones. *Pediatrics* 2006;118:1287-92.
- 24) Rizzato G, Montemurro L, Fraioli P, et al. Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia. *Eur Respir J* 1995; 8:398–402.
- 25) Rotstein C, Evans G, Born A, et al. Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults. *Can J Infect Dis Med Microbiol.* 2008;19:19-53.
- 26) Scalera NM, File TM Jr. How long should we treat community-acquired pneumonia? *Curr Opin Infect Dis* 2007;20:177-81.
- 27) Vanderkooi OG, Low DE, Green K et al. Predicting antimicrobial resistance in invasive pneumococcal infections. *Clin Infect Dis* 2005;40:1288-97.3
- 28) Vardakas KZ, Siempos II, Grammatikos A et al. Respiratory fluoroquinolones for the treatment of community-acquired pneumonia : a meta-analysis of randomized controlled trials. *CMAJ* 2008;179:1269-77.
- 29) Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. *Eur Respir J* 2005;26:1138-80.

PERTUSSIS

- 1) Altunajji SM, Kukuruzovic RH, Curtis NC, et al. Antibiotics for whooping cough (pertussis). (Cochrane Review). In: *The Cochrane Library*, Issue 3, 2007.
- 2) (Am Acad Peds, 2006) American Academy of Pediatrics Committee on Infectious Diseases. Prevention of Pertussis Among Adolescents: Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccine *Pediatrics* 2006 117: 965-978.
- 3) (CDC, 2005) Center for Disease Control 2005. January, 2005 Updates – Guidelines for the Control of Pertussis Outbreaks. Available: <http://www.cdc.gov/>
- 4) (NACI) National Advisory Committee on Immunization (2006). Recommended immunization. In *Canadian Immunization Guide*, 7th ed. Ottawa: Public Health Agency of Canada. <http://publications.gc.ca>.
- 5) (NACI) National Advisory Committee on Immunization. Statement on the recommended use of pentavalent and hexavalent vaccines. *Canada Communicable Disease Report Volume 33 ACS-1*. February 2007.
- 6) Tiwari T, Murphy TV, Moran J. Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis. 2005 CDC guidelines. *MMWR* 2005;54 (RR14):1-16. Available from: www.cdc.gov/mmwr/preview/mmwrhtml/rr5414a1.htm

SKIN INFECTIONS

IMPETIGO/CUTANEOUS INFECTIONS/CELLULITIS

- 1) Barton M, Hawkes M, Moore D, et al. Guidelines for the prevention and management of community-associated methicillin-resistant *Staphylococcus aureus*: a perspective for Canadian health care practitioners. *Can J Infect Dis Med Microbiol* 2006;17(Suppl C):4C.
- 2) Bergin S, Wraight P. Silver based wound dressings and topical agents for treating diabetic foot ulcers. (Cochrane Review). In: *The Cochrane Library*, Issue, 1, 2006.
- 3) Cole C, Gazewood J. Diagnosis and Treatment of Impetigo. *Am Fam Physician* 2007;75:859-64.
- 4) (CREST, 2005) Clinical Resources Efficiency Support Team: CREST guidelines on the management of cellulitis in adults. Available from: <http://www.crestni.org.uk/>
- 5) Eron LJ, Lipsky BA, Low DE, et al. Managing skin and soft tissue infections: Expert panel recommendations on key decision points. *JAC* 2003;52:Suppl. S1, i3–i17.
- 6) Falagas ME, Vergidis PI. Narrative review: diseases that masquerade as infectious cellulitis. *Ann Intern Med* 2005;142:47-55.
- 7) Frykberg RG, Zgonis T, Armstrong DG, et al. Diabetic Foot Disorders: A clinical practice guideline (2006 revision). *J Foot Ankle Surg* 2006;45(5 Suppl):S1-66.
- 8) Koning S, Verhagen AP, van Suijlekom-Smit LWA, et al. Interventions for impetigo. (Cochrane Review). In: *The Cochrane Library*, Issue 2, 2004.

- 9) Lipsky BA, Berendt AR, Deery HG, et al. Diagnosis and treatment of diabetic foot infections (IDSA guidelines). *Clin Infect Dis* 2004;39:885-910.
- 10) McIntosh A, Young R, Clarkson S, et al. Prevention and management of foot problems in type 2 diabetes: Clinical Guidelines and Evidence. Sheffield, University of Sheffield. Updated 2004.
- 11) Rose G, Duerksen F, Trepman E et al. Multi-disciplinary treatment of diabetic foot ulcers in Canadian Aboriginal and non-Aboriginal people. *Foot Ankle Surg.* 2008;14:74-81.
- 12) Sibbald RG, Woo KY, Ayello EA. Increased bacterial burden and infection: the story of NERDS and STONES. *Adv Skin Wound Care.* 2006; 19(8): 447–461.
- 13) Stevens DL, Bisno AL, Chambers HF, et al. (IDSA) Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections. *Clin Infect Dis* 2005;41:1373-1406.
- 14) University Health Network. Guidelines for antimicrobial use 2009. Toronto, ON, Canada.
- 15) (WATAG, 2006) Western Australian Therapeutics Advisory Group. Guidelines for the management and treatment of limb cellulitis in adults. Available from: <http://www.watag.org.au/watag/docs/Cellulitis%20Guideline.pdf>
- 16) Woo KY, Sibbald RG. A Cross-Sectional Validation study of using NERDS and STONEES to assess Bacterial Burden. *Ostomy Wound Management* 2009; 55(8): 40 – 48.
- 17) Woo KY, Ayello EA, Sibbald RG. The edge effect: Current therapeutic options to advance the wound edge. *Advances Skin Wound Care.* 2007; 20: 99-117.

CA-MRSA (COMMUNITY ACQUIRED METHICILLIN RESISTANT *S. AUREUS*)

1. Barton M, Hawkes M, Moore D, Conly J, Nicolle L, Allen U et al. The Writing Group of the Expert Panel of Canadian Infectious Disease. MRSA guidelines supplement. *Can J Infect Dis Med Microbiol.* 2006;(17):Suppl. SC 4-24.
2. Beam JW, Buckley B Community-Acquired Methicillin-Resistant *Staphylococcus aureus*: Prevalence and Risk Factors. *J Athl Train.* 2006 Jul-Sep;41(3):337-40.
3. Boyce JM, Cookson B, Christiansen, K. et al. Methicillin-resistant *Staphylococcus aureus*. 2005. *The Lancet Infectious Diseases* 2005;5(10):653–663.
4. Boyce JM. Community-associated methicillin resistant *Staphylococcus aureus* as a cause of health care-associated infection. *Clinical Infectious Diseases* 2008;46:795–798.
5. Conly J. Antimicrobial resistance in Canada. *CMAJ*, 2002;167(8):885-891.
6. Elliott DJ, Zaoutis TE, Troxel AB, Loh A, Keren R. Empiric antimicrobial therapy for pediatric skin and soft-tissue infections in the era of methicillin-resistant *Staphylococcus aureus* *Pediatrics* 2009;123:e959–e966
7. File TM. Impact of community-acquired methicillin-resistant *Staphylococcus aureus* in the hospital setting. *Cleveland Clin J Medicine.* 2007. 74 (Supp.4): S6-S11.
8. Gilbert M, MacDonald J, Gregson D et al. Outbreak in Alberta of community-acquired (USA 300) methicillin resistant *Staphylococcus aureus* in people with a history of drug use, homelessness or incarceration. *CMAJ* 2006; 175: 149-154
9. Gorwitz RJ, Jernigan DB, Powers JH, Jernigan JA, and Participants in the CDC (Centers for Diseases Control and Prevention) Convened Experts' Meeting on Management of MRSA in the Community. Strategies for clinical management of MRSA in the community: Summary of an experts' meeting convened by the CDC. 2006. (www.cdc.gov/)
10. Hidron AI, Kourbatova EV, Halvosa JS et al. Risk factors for colonization with methicillin-resistant *Staphylococcus aureus* (MRSA) in patients admitted to an urban hospital: Emergence of community-associated MRSA nasal carriage. *Clin Infect Dis.* 2005 Jul 15;41(2):159-66.
11. Johnston BL, Conly JM. Community-associated methicillin-resistant *Staphylococcus aureus*: Continuing to evolve. *Can J Infect Dis Med Microbiol.* 2008;19(2):161-163.

12. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S et al. Active Bacterial Core surveillance (ABCs) MRSA Investigators. Invasive methicillin-resistant *Staphylococcus aureus* infections in the United States JAMA. 2007;298(15):1763-1771.
13. Mulvey MR, MacDougall L, Cholin B, Horsman G, Fidyk M, Woods S; Saskatchewan CA-MRSA Study Group. Community-associated methicillin-resistant *Staphylococcus aureus*, Canada. Emerg Infect Dis 2005;11:844-50.
14. Nichol KA, McCracken M, DeCorby MR et al. Comparison of community-associated and health care-associated methicillin-resistant *Staphylococcus aureus* in Canada: Results from CANWARD 2007. Can J Infect Dis Med Microbiol. 2009; 20 (Suppl SA: 31-36).
15. Nicolle LE. Clinical practice: Community-associated methicillin resistant *Staphylococcus aureus*: A practitioner's guide. Can Med Assoc Jour 2006; 175:145-146.
16. Nicolle LE. Community-acquired MRSA-Getting over it. (editorial) Can J Infect Dis Med Microbiol 2005; 16:323-324.
17. Nathwani D, Morgan M, Masterton RG et al. Guidelines for UK practice for the diagnosis and management of methicillin-resistant *Staphylococcus aureus* (MRSA) infections presenting in the community. J Antimicrob Chemother. 2008;61(5):976-94.
18. Pennie R. Personal Communication. Brantford General Hospital. 2010.
19. (PIDAC) Best Practices for Infection Prevention and Control of Resistant *Staphylococcus aureus* and Enterococci: Ontario Provincial Infectious Diseases Advisory Committee. 2007.
20. Popovich, K.J., R.A. Weinstein, B. Hota. (2008) "Are community-associated methicillin-resistant *Staphylococcus aureus* (MRSA) strains replacing traditional nosocomial strains?" Clin Inf Dis 46:787-794.
21. Salgado CD, Farr BM, Calfee DP. Community acquired methicillin resistant *Staphylococcus aureus*: A meta-analysis of prevalence and risk factors. Clin Inf Dis 2003;36:131-139.
22. Simor AE, Loeb M. The management of infection and colonization due to methicillin-resistant *Staphylococcus aureus*: A CIDS/CAMM position paper. Can J Infect Dis 2004;15(1):39-48.
23. Simor AE, Ofner-Agostini M, Bryce E, Green K et al. The evolution of methicillin-resistant *Staphylococcus aureus* in Canadian hospitals: 5 years of national surveillance. CMAJ, 2001;165:21-26.
24. Skiest DJ, Brown K, Cooper TW, Hoffman-Roberts H, Mussa HR, Elliott AC. Prospective comparison of methicillin-susceptible and methicillin-resistant community-associated *Staphylococcus aureus* infections in hospitalized patients. J Infect. 2007 18(6):341-345.

BITES

- 1) Canadian Paediatric Society Position Statement. A bite in the playroom: Managing human bites in child care settings. Paed Child Health 2008;13:515-26.
- 2) Foreshew G. Treatment of animal and human bites in adults in the emergency department. Queens Medical Centre Nottingham, NHS. Septemeber 2006. Available from: www.nuh.nhs.uk
- 3) (HPA) Health Protection Agency Association of Medical Microbiologists. Management of Infection Guidance for primary care for consultation and local adaptation (UK). 2006. Available from: <http://www.hpa.org.uk/>
- 4) Medeiros I, Saconato H. Antibiotic prophylaxis for mammalian bites. (Cochrane Review). In: The Cochrane Library, Issue 2, 2001.
- 5) Morgan M, Palmer J. Clinical Review: Dog bites. BMJ 2007;334:413-7.
- 6) (PIER) Kravetz JD, Federman DG. Physicians' Information and Education Resource (PIER) ACP 2008. <http://pier.acponline.org>
- 7) Rittner AV, Fitzpatrick K, Corfield A. Best evidence topic report. Are antibiotics indicated following human bites? Emerg Med J 2005;22:654
- 8) Singer AJ, Dagum AB. Current management of acute cutaneous wounds. NEJM 2008;359:1037-46.
- 9) Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005;41:1373-406.

LYME DISEASE

- 1) Anonymous. Treatment of lyme disease. Med Lett 2007;1263:49.
- 2) Cameron D, Gaito A, Harris N, et al. Evidence-based guidelines for the management of Lyme disease. Exp Rev Antiinf Therapy 2004;2:S1-13.
- 3) Can Paed Soc (Canadian Paediatric Society). Lyme disease in Canada. Pediatr Child Health. 2009;14(3):103-5.

- 4) Halperin JJ, Shapiro ED, Logigian E, et al. Practice parameter: Treatment of nervous system Lyme disease (an evidence-based review). Report of the quality standards subcommittee of the American academy of neurology. *Neurology* 2007;69:91-102.
- 5) Ogden NH, Lindsay LR, Morshed M et al. The emergence of Lyme disease in Canada. *CMAJ.*, 2009;180(12): 1221-24.
- 6) Public Health Agency of Canada. National lyme disease meeting March 8-9, 2006. Released January 22, 2008. Available from: http://www.phac-aspc.gc.ca/id-mi/pdf/lyme032006_e.pdf
- 7) Wormser G, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment and prevention of lyme disease, human granulocytic anaplasmosis and babesiosis: Clinical practice guidelines by the infectious diseases society of America. *Clin Inf Dis* 2006;43:1089-134.

HERPES SIMPLEX VIRUS – MUCOCUTANEOUS

- 1) Anonymous. Docosanol 10% cream (Abreva). *Pharmacists Letter* 2005;21:211216.
- 2) Anonymous. Penciclovir 1% cream (Denavir). *Pharmacists Letter* 2006;22:221119.
- 3) Jones CA, Isaacs D. Management of herpes simplex virus infections. *Curr Paed* 2004;14:131-136.
- 4) Nasser M, Fedorowicz Z, Khoshnevisan MH, et al. Acyclovir for treating primary herpetic gingivostomatitis. (Cochrane Review). In: *The Cochrane Library*, Issue 4, 2008.

HERPES SIMPLEX VIRUS – KERATITIS OR KERATOCONJUNCTIVITIS

- 1) (AOA, 2002) American Optometric Association. Care of the patient with conjunctivitis 2nd ed. Available from: <http://www.aoa.org/documents/CPG-11.pdf>
- 2) Blondel-Hill E. and Fryters S. *Bugs and Drugs* (4th Ed.) 2006. Capital Health, Edmonton, AB.
- 3) Lairson DR, Begley CE, Reynolds TF, et al. Prevention of herpes simplex virus eye disease: a cost-effectiveness analysis. *Arch Ophthalmol* 2003;121:108-12.

VARICELLA ZOSTER VIRUS – SHINGLES

- 1) (CADTH) Canadian Coordinating Office for Health Technology Assessment. Vaccine for herpes zoster. Emerging drug list No 67 January 2006.: http://www.cadth.ca/media/pdf/412_No67_herpes_zoster_vaccine_edrug_e.pdf
- 2) Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. *Clin Inf Dis* 2007;44:S1-26.
- 3) He L, Zhang D, Zhou M, et al. Corticosteroids for preventing postherpetic neuralgia. (Cochrane Review). In: *The Cochrane Library*, Issue 1, 2008.
- 4) Harpaz R, Ortega-Sanchez IR, Seward JF, et al. Prevention of herpes zoster: Recommendations of the advisory committee on immunization practices (ACIP). *MMWR Recommendation and Reports* 2008;57:1-30.
- 5) Kempf W, Meylan P, Gerber S, et al. Swiss recommendations for the management of varicella zoster virus infections. *Swiss Med Wkly* 2007;137:239-51.
- 6) Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. *NEJM* 2007;356:1338-43.
- 7) Klassen TP, Belseck EM, Wiebe N, Hartling L. Acyclovir for treating varicella in otherwise healthy children and adolescents. *Cochrane Database Syst Rev* 2004: CD002980.
- 8) Marin M, Guris D, Chaves SS et al. Prevention of varicella : recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 2007;56:1.
- 9) Merck Frosst. Zostavax approved in Canada. www.merckfrosst.ca/assets/en/pdf/press/product_info/zostavax/pr_2008
- 10) (NACI) National Advisory Committee on Immunization. Statement on the recommended use of herpes zoster vaccine. *Canada Communicable Disease Report (CCDR)* 2010;36(ACS-1).
- 11) Wareham DW, Breuer J. Herpes zoster. *BMJ* 2007;334:1211-5.

CHICKEN POX

- 1) Allen S. Chickenpox and shingles infection. *PJ* 2006;277:453-456.
- 2) (Can Paed Soc) Infectious Diseases and Immunization Committee, Canadian Paediatric Society. Prevention of varicella in children and adolescents. *Paediatr Child Health* 2005;10:409-12.

- 3) Klassen TP, Hartling L, Wiebe N, et al. Acyclovir for treating varicella in otherwise healthy children and adolescents. (Cochrane Review). In: The Cochrane Library, Issue 4, 2005.
- 4) Macartney K, McIntyre P. Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults. (Cochrane Review). In: The Cochrane Library, Issue 3, 2008.
- 5) Marin M, Guris D, Chaves SS et al: Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2007; 56(RR-4):1-40.
- 6) (NACI)(a) National Advisory Committee on Immunization. *Canadian Immunization Guide*. 7th edition. Ottawa (ON): Public Health Agency of Canada; 2006. Available from: http://www.phac-aspc.gc.ca/publicat/cig-gci/pdf/cig-gci-2006_e.pdf.
- 7) (NACI)(b) National Advisory Committee on Immunization. Varizig™ as the varicella zoster immune globulin for the prevention of varicella in at-risk patients. Canada Communicable Disease Report (CCDR). 2006;32(ACS-8).
- 8) (NHS-CKS) National Health Services-Clinical Knowledge Summaries. (formerly Prodigy) Available at: <http://cks.library.nhs.uk/>
- 9) (RCOG, 2007) Royal College of Obstetricians and Gynaecologists. Chickenpox in pregnancy. Green-top guideline 13; September 2007. Available from: <http://www.rcog.org.uk/>
- 10) Watson B, Seward J, Yang A et al. Postexposure effectiveness of varicella vaccine. Pediatrics 2000;05:84-8.

GENITOURINARY

UTI-Epididymitis

1. American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001;108(3):776-89.
2. (BASHH, 2008) British Association for Sexual Health and HIV. National guidelines for the management of prostatitis. 2003. Available at: <http://www.bashh.org/>
3. Bauer R, Kogan BA. New developments in the diagnosis and management of pediatric UTIs. Urol Clin North Am 2008;35(1):47-58.
4. Baumer JH, Jones RW. Urinary tract infection in children. National Institute for Health and Clinical Excellence. Arch Dis in Child Ed Prac 2007;92:189-92.
5. Beier MT. Management of Urinary tract infections in the nursing home elderly: a proposed algorithmic approach. Int J Antimicrob Agents. 1999;11(3-4):275-84
6. Bhullar S, Lele SM, Kraman S et al. Severe nitrofurantoin lung disease resolving without the use of steroids. J Postgrad Med 2007;53:111-3.
7. Benway BM, Moon TD. Bacterial prostatitis. Urol Clin North Am 2008;35(1):23-32.
8. Blondeau JM. Current issues in the management of urinary tract infections: Extended-release ciprofloxacin as a novel treatment option. Drugs 2004;64:611-28.
9. Boscia JA, Abrutyn E, Levison ME, Pitsakis PG, Kaye D. Pyuria and asymptomatic bacteriuria in elderly ambulatory women. Ann Intern Med 1989;110:404-5.
10. (CAN STI) Canadian STI Guidelines 2008. Expert Working Group for the Canadian Guidelines on Sexually Transmitted Infections. Wong T. (chair). Revised version of the 2006 edition. www.publichealth.gc.ca/sti
11. Canadian STD Guidelines (2006 ed.). Available at: http://www.phac-aspc.gc.ca/std-mts/sti_2006/pdf/
12. (CDC, 2006) Centers for Disease Control and Prevention. Sexually Transmitted Disease Treatment Guidelines 2006. MMWR 2006;55(RR-11):1-100.
13. Chang SL, Shortliffe LD. Pediatric urinary tract infections. Pediatr Clin North Am 2006;53:379-400.
14. Christiaens TC, DeMeyere M, Versciraegen G, et al. Randomised controlled trial of nitrofurantoin versus placebo in the treatment of uncomplicated urinary tract infection in adult women. Br J Gen Pract 2002;52:729-34.
15. Colgan R, Nicolle LE, McGlone A et al. Asymptomatic bacteriuria in adults. Am Fam Physician 2006;7:985-90.
16. Conway PH, Cnaan A, Zaoutis T, et al. Recurrent urinary tract infections in children: risk factors and association with prophylactic antimicrobials. JAMA 2007;298:179-86.
17. Craig JC, Simpson JM, Williams GJ et al. Antibiotic prophylaxis and recurrent urinary tract infection in children. NEJM 2009;361:1748-59.
18. Czaja CA, Hooton TM. Update on acute uncomplicated urinary tract infection in women. Postgrad Med 2006;119(1):39-45.

19. Falagas ME, Betsi GI, et al. Probiotics for prevention of recurrent urinary tract infections in women: a review of the evidence from microbiological and clinical studies. *Drugs* 2006;66:1253-61.
20. Ferry SA, Holm LSE, Stenlund H et al. The natural course of uncomplicated lower urinary tract infection in women illustrated by a randomized controlled study. *Scand J Infect Dis* 2004;36:296-301.
21. Fihn SD. Clinical practice. Acute uncomplicated urinary tract infection in women. *N Engl J Med* 2003;349:259-66.
22. Fitzgerald A, Lee CW, Mori R. Antibiotics for treating uncomplicated urinary tract infection in children. *Cochrane Database Syst Rev* 2007;(4):CD006857.
23. Fitzgerald MA, Lie D, Nettina SM. Urinary tract infection: providing the best care. Available at: <http://www.medscape.com/viewprogram/1920>
24. Forsythe CT, Ernst ME. Do fluoroquinolones commonly cause arthropathy in children? *CJEM* 2007;9:459-62.
25. Gupta K, Hooton T, Roberts P, Stamm W. Short course nitrofurantoin for the treatment of acute, uncomplicated cystitis in women. *Arch Intern Med.* 2007;167:2207-12.
26. Grabe M, Bishop MC, Bjerkklunk-Johansen TE et al. Guidelines of Urological Infections. *Eur J Urol* 2009. Available at: http://www.uroweb.org/fileadmin/tx_eauguidelines/2009/Full/Urological_Infections.pdf
27. Habermacher GM, Chason JT, Schaeffer AJ. Prostatitis/chronic pelvic pain syndrome. *Annu Rev Med* 2006;57:195-206.
28. Hoberman A, Charron M, Hickey RW et al. Imaging studies after a first febrile urinary tract infection in young children. *N Engl J Med* 2003;16:348:195-202.
29. Hollier LM, Workowski K Treatment of sexually transmitted infections in women. *Infect Dis Clin North Am.* 2008 Dec;22(4):665-91, vi.
30. Hooton TM. Recurrent urinary tract infection in women. *Int J Antimicrob Agents* 2001;17:259-68.
31. Hooton TM, Scholes D, Gupta K et al. Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial. *JAMA* 2005;293:949-55.
32. (ICSI, 2006) Institute for Clinical Systems Improvement. Uncomplicated urinary tract infection in women 2006. Available at: http://www.icsi.org/urinary_tract_infection/uncomplicated_urinary_tract_infection_in_women_2.html
33. Jepson R, Craig J. Cranberries for preventing urinary tract infections. *Cochrane Database Syst Rev* 2008;23(1):CD001321.
34. Juthani-Mehta M Asymptomatic bacteriuria and urinary tract infection in older adults. *Clin Geriatr Med* 2007; 23(3): 585-94.
35. Juthani-Mehta M, Tinetti M, Perrelli E, et al. Diagnostic accuracy of criteria for urinary tract infection in a cohort of nursing home residents. *J Am Geriatr Soc.* 2007;55(7):1072-7.
36. Klimberg IW et al. A controlled trial of levofloxacin and lomefloxacin in the treatment of complicated urinary tract infection. *Urology* 1998;51:610-5.
37. Kontiokari T, Sundqvist K, Nuutinen M et al. Randomised trial of cranberry-lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women. *BMJ* 2001;322:1571-3.
38. Karlowsky JA, Hoban, DJ, DeCorby MR, Laing NM, Zhanel GG. Fluoroquinolone-Resistant Urinary Isolates of *Escherichia coli* from Outpatients Are Frequently Multidrug Resistant: Results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance Study. *Antimicrobial agents and chemotherapy.* 2006;50(6):2251-54.
39. Koulaouzidis A, Bhat S, Moschos J et al. Nitrofurantoin-induced lung- and hepatotoxicity. *Ann Hepatol* 2007;6:119-21.
40. Koyle MA, Barqawi A, Wild J, et al. Pediatric urinary tract infections: the role of fluoroquinolones. *Pediatr Infect Dis J* 2003;12:1133-7.
41. Kropp RY, Latham-Carmanico C, Steben M, et al. What's new in management of sexually transmitted infections? *Can Fam Physician* 2007;53:1739-41.
42. Kummire LD, Donofrio PD. Nitrofurantoin neuropathy forgotten adverse effect. *Obstet Gynecol* 2007;110:510-2.
43. Laupland KB, Ross T, Pitout JD, Church DL, Gregson DB. Community-onset Urinary Tract Infections: A population-based assessment. *Infection* 35(4): 150-3, 2007.
44. Little P, Moore MV, Turner S, Rumsby K et al. Effectiveness of five different approaches in management of urinary tract infection: randomised controlled trial *BMJ* 2010;340:c199 doi:10.1136/bmj.c199

45. Loeb M, Brazil K, Lohfeld L, et al. Effect of a multifaceted intervention on number of antimicrobial prescriptions for suspected urinary tract infections in residents of nursing homes: Cluster randomised controlled trial. *BMJ*. 2005;331(7518):669.
46. Lee BB, Simpson JM, Craig JC et al. Methenamine hippurate for preventing urinary tract infections. *Cochrane Database Syst Rev* 2007;(4):CD003265.
47. Lutters, M. Vogt-Ferrier, NB. Antibiotic duration for treating uncomplicated, symptomatic lower urinary tract infections in elderly women. [Systematic Review] *Cochrane Renal Group Cochrane Database of Systematic Reviews*. 4, 2007.
48. Macejko AM. Asymptomatic bacteriuria and symptomatic urinary tract infections during pregnancy. *Urol Clin North Am* 2007;34(1): 35-42.
49. Monette J, Miller MA, Monette M, et al. *J Am Geriatr Soc*.2007 Aug;55(8):1231-5.
50. McDermott S, Daguise V, Mann H et al. Perinatal risk for mortality and mental retardation associated with maternal urinary-tract infections. *J Fam Pract* 2001;50(5):433-7.
51. McIsaac WJ, Low DE, Biringner A et al. The impact of empirical management of acute cystitis on unnecessary antibiotic use. *Arch Intern Med* 2002;162:600-5.
52. McIsaac WJ, Moineddin R, Ross S. Validation of a decision aid to assist physicians in reducing unnecessary antibiotic drug use for acute cystitis. *Arch Intern Med* 2007;167:2201-06.
53. McLaughlin SP, Carson CC. Urinary tract infections in women. *Med Clin North Am* 2004; 88(2):417-29.
54. Milo G, Katchman EA, Paul M et al. Duration of antibacterial treatment for uncomplicated urinary tract infection in women. *Cochrane Database Syst Rev* 2005;18(2):CD004682.
55. Mittal P, Wing DA. Urinary tract infections in pregnancy. *Clin Perinatol* 2005;32:749-64.
56. Mori R, Lakhanpaul M, Verrier-Jones K. Diagnosis and management of urinary tract infection in children: Summary of NICE guidance. *BMJ* 2007;335:395-7.
57. Moura A, Nicolau A, Hooton T et al. Antibiotherapy and pathogenesis of uncomplicated UTI: difficult relationships. *J App Microbiol* 2009;106:1779-91.
58. Murray TS, Baltimore RS. Pediatric uses of fluoroquinolone antibiotics. *Pediatr Ann* 2007;36:336-42.
59. Neal Jr DE. Complicated urinary tract infections. *Urol Clin North Am* 2008;35(1):13-22.
60. (NICE) National Collaborating Centre for Women's and Children's Health. Urinary tract infection in children: diagnosis, treatment and long-term management. London, UK: National Institute for Health and Clinical Excellence 2007. Available at: <http://guidance.nice.org.uk/CG54>
61. Nickel JC, Downey J, Clark J et al. Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo-controlled multicenter trial. *Urol* 2003;62:614-7.
62. Nickel JC, Moon T. Chronic bacterial prostatitis: an evolving clinical enigma. *Urol* 2005;66:2-8.
63. Nicolle LE(a), Anderson PA, Conly J et al. Uncomplicated urinary tract infection in women. Current practice and the effect of antibiotic resistance on empiric treatment. *Can Fam Physician* 2006;52:612-8.
64. Nicolle LE(b). Asymptomatic bacteriuria: review and discussion of the IDSA guidelines. *Int J Antimicrob Agents* 2006;28(Suppl 1):S42-8.
65. Nicolle LE, SHEA Long-Term Care Committee Urinary tract infections in long-term-care facilities. *Infect Control Hosp Epidemiol*. 2001;22(3):167-75.
66. Nicolle LE(a). Short-term therapy for urinary tract infections: Success and failure. *Int J. Antimicrob Agents*. 2008;31 Suppl 1:S40-5.
67. Nicolle LE(b). Uncomplicated urinary tract infection in adults including uncomplicated pyelonephritis. *Urol Clin North Am* 2008;35:1-12.
68. Nicolle LE. Urinary infections in the elderly: symptomatic or asymptomatic? *Int J Antimicrob Agents*. 1999;11(3-4):265-8.
69. Nicolle LE. Urinary tract infection in long-term-care facility residents. *CID*.2000;31(3):757-61.
70. Nicolle LE(a), Evans G, Laverdieu M et al. Association of Medical Microbiology and Infectious Disease Canada Guidelines Committee. Complicated urinary tract infection in adults. *Can J Infect Dis Med Microbiol* 2005;16:349-60.
71. Nicolle LE(b), Bradley S, Colgan R et al. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. *Clin Infect Dis* 2005;40:643-54.
72. Nicolle LE(c), Duckworth H, Sitar D, et al. Pharmacokinetics/pharmacodynamics of levofloxacin 750 mg once daily in young women with acute uncomplicated pyelonephritis. *Int J Antimicrob Agents* 2008;31:287-91.
73. Nicolle LE. Symptomatic urinary tract infection in nursing home residents. *J Am Geriatr Soc* 2009;57:1113-4.

74. O'Donnell JA, Hofmann MT. Urinary tract infections. How to manage nursing home patients with or without chronic catheterization. *Geriatrics*. 2002;57(5):45, 49-52, 55-6
75. Orenstein R, Wong ES. Urinary tract infections in adults. *Am Fam Physician* 1999;59:1225-34.
76. Orr PH, Nicolle LE, Duckworth H, Brunka J, Kennedy J, Murray D, et al. Febrile urinary infection in the institutionalized elderly. *Am J Med* 1996;100:71-7.
77. Peterson J, Kaul S, Khashab M, Fisher AC, Kahn JB. Double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. 2008.*Urology*. 71(1):17-22
78. Ramakrishnan K, Scheid DC. Diagnosis and management of acute pyelonephritis in adults. *Am Fam Physician* 2005;71:933-42.
79. Reid G, Bruce AW. Probiotics to prevent urinary tract infections: the rationale and evidence. *World J Urol* 2006;24:28-32.
80. Sanchez-Ramos L, McAlpine KJ, Adair CD et al. Pyelonephritis in pregnancy: once-a-day ceftriaxone versus multiple doses of ceftazolin. A randomized, double-blind trial. *Am J Obstet Gynecol* 1995;172(1 Pt 1):129-33.
81. Schaeffer AJ. Clinical practice. Chronic prostatitis and the chronic pelvic pain syndrome. *N Engl J Med* 2006;355:1690-8.
82. Shah G, Upadhyay J. Controversies in the diagnosis and management of urinary tract infections in children. *Paediatr Drugs* 2005;7:339-46.
83. Schattner A, Von der Walde J, Kozak N et al. Nitrofurantoin-induced immune-mediated lung and liver disease (case report). *Am J Med Sci* 1999;317:336-40.
84. (SIGN, 2006) Scottish Intercollegiate Guidelines Network 2006. Management of suspected bacterial urinary tract infection in adults 2006. Available at: <http://www.sign.ac.uk/pdf/sign88.pdf>
85. Shaikh N, Morone NE, Lopez J et al. Does this child have a urinary tract infection? *JAMA* 2007;298:2895-904.
86. Sheffield JS, Cunningham FG. Urinary tract infection in women. *Obstet Gynecol* 2005;106:1085-92.
87. Shrim A. Pharmaceutical agents and pregnancy in urology practice. *Urol Clin North Am* 2007;34(1):27-33.
88. Smith L. Updated CDC guidelines for the treatment of STDs. *Am Fam Physician* 2007;75:560-9.
89. Smaill F, Vazquez JC. Antibiotics for asymptomatic bacteriuria in pregnancy. *Cochrane Database Syst Rev* 2007;(2):CD000490.
90. Stein GE. Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection. *Clinical Therapeutics* 1999;21:1864-72.
91. Stothers L. A randomized trial to evaluate effectiveness and cost effectiveness of naturopathic cranberry products as prophylaxis against urinary tract infection in women. *Can J Urol* 2002;3:1558-62.
92. University of Michigan Health System 2005. Urinary tract infection. Available at: <http://cme.med.umich.edu/pdf/guideline/UTI05.pdf>
93. Vazquez JC, Villar J. Treatments for symptomatic urinary tract infections during pregnancy. *Cochrane Pregnancy and Childbirth Group Cochrane Database Syst Rev* 2003;(4):CD002256.
94. Wagenlehner FM, Weidner W, Naber KG. Therapy for prostatitis, with emphasis on bacterial prostatitis. *Expert Opin Pharmacother* 2007;8:1667-74.
95. Wagenlehner FM(a), Naber KG. Current challenges in the treatment of complicated urinary tract infections and prostatitis. *Clin Microb and Infect* 2006;12(Suppl 3):67-80.
96. Wagenlehner FM(b), Naber KG. Treatment of bacterial urinary tract infections: presence and future. *Eur Urol* 2006;49:235-44.
97. Wagenlehner FM (c), Redman R, Weidner W, Naber KG. Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. *Antimicrobial Agents & Chemotherapy*. 2009;53(4):1567-73.
98. Walker S, McGeer A, Simor AE, Armstrong-Evans M, Loeb M. Why are antibiotics prescribed for asymptomatic bacteriuria in institutionalized elderly people? *CMAJ* 2000;163(3):
99. Williams EM, Triller DM. Recurrent acute nitrofurantoin-induced pulmonary toxicity. *Pharmacotherapy* 2006;26:713-8.
100. Williams G, Craig JC. Prevention of recurrent urinary tract infection in children. *Curr Opin Infect Dis* 2009;22:72-6.
101. Zhanel et al. Antibiotic resistance in *Escherichia coli* outpatient urinary isolates: Final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). *Int J Antimicrob Agents* 2006;27(6):468-475.

102.Zorc JJ, Kiddoo DA, Shaw KN. Diagnosis and management of pediatric urinary tract infections. Clin Microbiol Rev 2005;18(2):417-22.

SEXUALLY TRANSMITTED INFECTIONS (STI)

1. Alberta Treatment Guidelines for Sexually Transmitted Infections (STI) in adolescents and adults. 2008. <http://www.health.alberta.ca/>
2. (CAN STI) Canadian STI Guidelines 2008. Expert Working Group for the Canadian Guidelines on Sexually Transmitted Infections. Wong T. (chair). Revised version of the 2006 edition. www.publichealth.gc.ca/sti
3. (CDC 2006) Centers for Disease Control and Prevention. Sexually Transmitted Disease Treatment Guidelines 2006.MMWR 2006;55(RR-11):1-100.
4. Hollier LM, Workowski K Treatment of sexually transmitted infections in women.Infect Dis Clin North Am. 2008 Dec;22(4):665-91, vi.
5. Lo JYC, Ho KM, Leung AOC, et al. Cefitibuten resistance and treatment failure in gonococcal infection. Antimicrob Agents Chemother 2008;52:3564-7.
6. Ota KV, Jamieson F, Fisman DN, et al. Prevalence of and risk factors for quinolone-resistant *Neisseria gonorrhoeae* infection in Ontario. CMAJ 2008;180:287-90.
7. Workowski KA, Berman SM, Douglas JM Jr. Emerging antimicrobial resistance in *Neisseria gonorrhoeae*: urgent need to strengthen prevention strategies. Ann Intern Med 2008;148:606-13.
8. Yokoi S, Deguchi T, Ozawa T, et al. Threat to cefixime treatment for gonorrhea. Emerg Infect Dis 2007;13:1275-7.

PELVIC INFLAMMATORY DISEASE TO VULVO VAGINAL CANDIDIASIS (VVC)

1. Aleck KA, Bartley DL. Multiple malformation syndrome following fluconazole use in pregnancy: report of an additional patient. Am J Med Genet. 1997;72:253-6.
2. (BASHH 2005) British Association for Sexual Health and HIV. Management of PID. <http://www.bashh.org/>
3. (CAN STI 2008) Canadian Guidelines on Sexually Transmitted Infections.(2006 ed.- Updated 2008). Available at: <http://www.phac-aspc.gc.ca/>
4. (CDC 2006) Centers for Disease Control and Prevention. Sexually Transmitted Disease Treatment Guidelines 2006.MMWR 2006;55(RR-11):1-100
5. Einarson A, Koren G. Bacterial vaginosis during pregnancy. Should we screen for and treat it? Can Fam Physician. 2002; 48: 877-8.
6. Falagas ME, Betsi GI, Athanasion S. Probiotics for the treatment of women with bacterial vaginosis. Clin Microbiol Infect. 2007;13:657-64
7. Ferris DG, Litaker MS, Woodward L, et al. Treatment of bacterial vaginosis: a comparison of oral metronidazole, metronidazole vaginal gel, and clindamycin vaginal cream. J Fam Pract. 1995;41:443-9.
8. Forna, F, Gulmezoglu, AM. Interventions for treating trichomoniasis in women. [Systematic Review] Cochrane Infectious Diseases Group Cochrane Database of Systematic Reviews. 4, 2007.
9. Gulmezoglu AM. Interventions for trichomoniasis in pregnancy. [Systematic Review] Cochrane Pregnancy and Childbirth Group Cochrane Database of Systematic Reviews. 4, 2007.
10. Haggerty CL, Ness RB. Newest approaches to treatment of pelvic inflammatory disease: a review of recent randomized clinical trials. Clin Infect Dis.2007;44:953-60 (Abstract).
11. Hanson JM, McGregor JA, Hiller SL, et al. Metronidazole for bacterial vaginosis. A comparison of vaginal gel vs. oral therapy. J Reprod Med. 2000;45:889-96.
12. Klebanoff MA, Guise JM, Carey JC. Treatment recommendations for bacterial vaginosis in pregnant women. Clin Infect Dis. 2003;36:1630-1.
13. Livengood CH, Soper DE, Sheehan KL, et. al. Comparison of once-daily and twice-daily dosing of 0.75% metronidazole gel in the treatment of bacterial vaginosis. Sex Transm Dis. 1999 Mar;26:137-42.
14. Majeroni BA, Ukkadam S. Screening and treatment for sexually transmitted infections in pregnancy. Am Fam Physician. 2007;76:265-70.
15. McDonald HM, Brocklehurst P, Gordon A. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev. 2007;(1):CD000262. Review

16. Nurbhai M, Grimshaw J, Watson M, et al. Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). *Cochrane Database Syst Rev*. 2007;(4):CD002845. Review.
17. Nygren P, Fe R, Guise JM, et al. Evidence on the benefits and harms of screening and treating pregnant women who are asymptomatic for bacterial vaginosis: an update review for the U.S. Preventive Services Task Force. *Ann Intern Med*. 2008;148:220-33.
18. Okun N, Gronau KA, Hannah ME. Antibiotics for bacterial vaginosis or *Trichomonas vaginalis* in pregnancy: a systematic review. *Obstet Gynecol*. 2005;105:857
19. Ozkinay E, Terek MC, Yayci M, et al. The effectiveness of live lactobacilli in combination with low dose oestriol (Gynoflor) to restore the vaginal flora after treatment of vaginal infections. *BJOG*. 2005;112:234-40.
20. Parent D, Bossens M, Bayot D, et al. Therapy of bacterial vaginosis using exogenously-applied *Lactobacilli acidophili* and a low dose of estriol: a placebo-controlled multicentric clinical trial. *Arzneimittelforschung*. 1996;46:68
21. Pirotta M, Gunn J, Chondros P. et al. Effect of lactobacillus in preventing post-antibiotic vulvovaginal candidiasis: a randomized controlled trial. *BMJ*. 2004; 329: 548-52.
22. Prodigy Guidance. *Trichomoniasis* 2006. <http://www.nelm.nhs.uk/>
23. Pursley TJ, Blomquist IK, Abraham J, et al. Fluconazole-induced congenital anomalies in three infants (abstract). *Clin Infect Dis*. 1996;22(2):336-40.
24. Probiotics discussion paper. Health Canada. 2006. Available: www.hc-sc.gc.ca/
25. Reid G, Charbonneau D, Erb J. et al. Oral use of *Lactobacillus rhamnosus* GR-1 and *L. fermentum* RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women. *FEMS Immunol Med Microbiol*. 2003 ;35(2):131-4
26. Ross J, Judlin P, Nilas L. European guideline for the management of pelvic inflammatory disease *Int J STD AIDS*. 2007 Oct;18(10):662-6.
27. Ross JD, Cronje HS, Paszkowski T et al. MAIDEN Study Group. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial. *Sex Transm Infect*. 2006;82(6):446-51.
28. Savaris RF, Teixeira LM, Torres TG. et al. Comparing ceftriaxone plus azithromycin or doxycycline for pelvic inflammatory disease: a randomized controlled trial. *Obstet Gynecol*.2007;110:53-60.
29. Senok, AC, Verstraelen, H, Temmerman, M, Botta, GA. Probiotics for the treatment of bacterial vaginosis. [Protocol] *Cochrane Sexually Transmitted Diseases Group Cochrane Database of Systematic Reviews*. 4, 2007.
30. Smith KJ, Ness RB, Wiesenfeld HC, Roberts MS. Cost-effectiveness of alternative outpatient pelvic inflammatory disease treatment strategies. *Sex Transm Dis*. 2007;34:960-6.
31. Sobel JD, Vulvovaginal candidosis. *Lancet*. 2007;369:1961-71.
32. Van Vranken M. Prevention and treatment of sexually transmitted diseases: an update. *Am Fam Physician*. 2007;76(12): 1827-32.

URETHRITIS-EGW

1. ACOG Committee on Practice Bulletins. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. No. 82 June 2007. Management of herpes in pregnancy. *Obstet Gynecol*. 2007;109:1489-98.
2. Aoki FY. Genital herpes simplex virus (HSV) infections. In: *Canadian guidelines on sexually transmitted infections*. 2006 edition. Ottawa (ON): Public Health Agency of Canada; 2006. <http://www.phac-aspc.gc.ca/>
3. Aoki FY, Tyring S, Diaz-Mitoma F, et al. Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. *Clin Infect Dis*. 2006;42:8-13.
4. (BASHH 2007) British Association for Sexual Health and HIV. United Kingdom National Guideline. <http://www.bashh.org/guidelines/2007/NatGuideMgxAGW2007.pdf>
5. Brady RC, Bernstein DI. Treatment of herpes simplex virus infections. *Antiviral Res* 2004;61:73-81.
6. Brocklehurst, P. Antibiotics for gonorrhoea in pregnancy. *Cochrane Pregnancy and Childbirth Group Cochrane Database of Systematic Reviews*. 4, 2007.
7. (CAN STI) Canadian STI Guidelines 2008. Expert Working Group for the Canadian Guidelines on Sexually Transmitted Infections. Wong T. (chair). Revised version of the 2006 edition. www.publichealth.gc.ca/sti
8. Canadian STD Guidelines 2006. http://www.phac-aspc.gc.ca/std-mts/sti_2006/pdf/sti2006_e.pdf

9. (CDC 2006) Centers for Disease Control and Prevention. Sexually Transmitted Disease Treatment Guidelines 2006. *MMWR* 2006;55(RR-11):1-100
10. Einarson A, Costei A, Kalra S, et al. The use of topical 5% imiquimod during pregnancy: a case series. *Reprod Toxicol.* 2006;21:1-2.
11. Finnish Medical Society Duodecim. Chlamydial urethritis and cervicitis. 2006. www.guidelines.gov
12. Gupta R, Warren T, Wald A. Genital herpes. *Lancet.* 2007;370:2127-37.
13. Kodner CM, Nasraty S. Management of genital warts. *Am Fam Physician.* 2004;70:2335-42.
14. Leone PA, Trottier S, Miller JM. Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment. *Clin Infect Dis.* 2002;34(7):958-62.
15. Lusk MJ, Konecny P. Cervicitis: a review. *Curr Opin Infect Dis.* 2008;21:49-55.
16. O'Mahony C. Genital warts: current and future management options. *Am J Clin Dermatol.* 2005;6:239-43.
17. Patel R, Rompalo A. Managing patients with genital herpes and their sexual partners. *Infect Dis Clin North Am.* 2005;19(2):427-38.
18. Prodigy guidance. Urethritis-male 2007. Available at: <http://www.prodigy.nhs.uk>.
19. Scott LL, Hollier LM, McIntire D, et al. Acyclovir suppression to prevent recurrent genital herpes at delivery. *Infect Dis Obstet Gynecol.* 2002;10:71-7.
20. Sen P, Barton SE. Genital herpes and its management. *BMJ.* 2007;334:1048-52.
21. Sheffield JS, Hill JB, Hollier LM, et al. Valacyclovir prophylaxis to prevent recurrent herpes at delivery: a randomized clinical trial. *Obstet Gynecol.* 2006;108(1):141-7.
22. Spruance SL, Hamill ML, Hoge WS et al. Acyclovir prevents reactivation of herpes simplex labialis in skiers. *JAMA* 1988;260:1597-99.
23. Van Vranken M. Prevention and treatment of sexually transmitted diseases: an update. *Am Fam Physician.* 2007;76:1827-32.
24. Wald A, Carrell D, Remington M, et al. Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. *Clin Infect Dis.* 2002;34:944-8.
25. Watts DH, Brown ZA, Money D, et al. A double-blind, randomized, placebo-controlled trial of acyclovir in late pregnancy for the reduction of herpes simplex virus shedding and cesarean delivery. *Am J Obstet Gynecol.* 2003;188:836-43

CENTRAL NERVOUS SYSTEM

BACTERIAL MENINGITIS – ADULT

- 1) Blondel-Hill E. and Fryters S. *Bugs and Drugs* (4th Ed.) 2006. Capital Health, Edmonton, AB.
- 2) Chaudhuria A, Martinb PM, Kennedyc PGE et al. EFNS guideline on the management of community-acquired bacterial meningitis: report of an EFNS Task Force on acute bacterial meningitis in older children and adults. *Eur J Neurol* 2008; 15:649–59.
- 3) Gardner P. Clinical practice. Prevention of meningococcal disease. *N Engl J Med.* 2006 Oct 5;355:1466-73.
- 4) Gilbert DN, Moellering Jr. RC, Eliopoulos GM, et al. *Sanford Guide to Antimicrobial Therapy* 38th Ed. Antimicrobial Therapy Inc. 2008.
- 5) (NACI) National Advisory Committee on Immunization. *Canadian Immunization Guide*. 7th edition. Ottawa (ON): Public Health Agency of Canada; 2006. Available from: http://www.phac-aspc.gc.ca/publicat/cig-gci/pdf/cig-gci-2006_e.pdf.
- 6) Tunkel AR, Hartman BJ, Kaplan SL et al. IDSA Practice guidelines for the management of bacterial meningitis. *Clin Infect Dis* 2004;39:1267-84.
- 7) Van de Beek D, de Gans J, McIntyre P et al. Corticosteroids for acute bacterial meningitis. (Cochrane Review). In: *The Cochrane Library*, Issue 1, 2007.
- 8) Van de Beek D, de Gans J, Tunkel AR, et al. Community-acquired bacterial meningitis in adults. *N Engl J Med* 2006;354:44-53.

BACTERIAL MENINGITIS – CHILDREN

- 1) (AAP) American Academy of Pediatrics, Committee on Infectious Diseases. *Red Book®: 2006 Report of the Committee on Infectious Diseases - 27th Ed.*

- 2) Bilukha, OO, Rosenstein, N. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Morb Mortal Wkly Rep* 2005; 54(RR-7):1.
- 3) Blondel-Hill E. and Fryters S. *Bugs and Drugs* (4th Ed.) 2006. Capital Health, Edmonton, AB.
- 4) Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Therapy of suspected bacterial meningitis in Canadian children six weeks of age and older. *Paediatr Child Health* 2008;13:309. Available at: <http://www.cps.ca/english/statements/ID/ID07-03.htm>.
- 5) Chaudhuria A, Martinb PM, Kennedyc PGE, et al. EFNS guideline on the management of community-acquired bacterial meningitis: report of an EFNS Task Force on acute bacterial meningitis in older children and adults. *Eur J Neurol* 2008; 15: 649–59.
- 6) Gilbert DN, Moellering Jr. RC, Eliopoulos GM, et al. *Sanford Guide to Antimicrobial Therapy* 38th Ed. Antimicrobial Therapy Inc. 2008.
- 7) (NACI) National Advisory Committee on Immunization. *Canadian Immunization Guide*. 7th edition. Ottawa (ON): Public Health Agency of Canada; 2006. Available from: http://www.phac-aspc.gc.ca/publicat/cig-gci/pdf/cig-gci-2006_e.pdf.
- 8) (SIGN, 2008) Scottish Intercollegiate Guidelines Network. Management of invasive meningococcal disease in children and young people. May 2008. Available at: <http://www.sign.ac.uk/>
- 9) U.S. Food and Drug Administration. Information for Healthcare Professionals. Ceftriaxone (marketed at Rocephin). Available at: <http://www.fda.gov/cder/drug/infosheets/hcp/ceftriaxone.htm>.
- 10) Van de Beek D, de Gans J, McIntyre P, et al. Corticosteroids for acute bacterial meningitis. (Cochrane Review). In: *The Cochrane Library*, Issue 1, 2007.

GASTROINTESTINAL

H.PYLORI- POSITIVE PEPTIC ULCER DISEASE

- 1) Alberta Medical Association. Guideline for Treatment of Helicobacter Pylori Infection in Adults. Toward Optimized Practice. 2007 Update. Available at: http://www.cdf.sld.cu/Biblioteca%20virtual/Digestivo/GPC-tratamiento%20h_pylori.pdf.
- 2) British Columbia Medical Association. Guidelines and Protocols Advisory Committee. *Helicobacter pylori* Infection Detection - Treatment in Adult Patients. 2003. Available at: http://www.bcguidelines.ca/gpac/guideline_helicobacter.html
- 3) Chey WD, Wong BCY. American College of Gastroenterology Guideline on the Management of Helicobacter pylori Infection. *Am J Gastroenterol* 2007;102:1808-1825.
- 4) Egan BJ, Katicic M, O'Connor HJ, O'Morain CA. Treatment of Helicobacter pylori. *Helicobacter* 2007;12(supp 1): 31-37.
- 5) Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. *Cochrane Database of Systematic Reviews* 2006, Issue 2. Art. No.: CD003840. DOI: 10.1002/14651858.CD003840.pub4.
- 6) Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. *Aliment Pharmacol Ther* 2006;23:35–44.
- 7) Graham DY et al. The Year in Helicobacter, 2007. *Helicobacter*. 12 (Suppl.1): 1-53. http://www.helicobacter.org/content/publications/helicobacter_2007/TheYearInHelicobacter2007.pdf
- 8) H. pylori treatment regimens. *Pharmacist's Letter/Prescriber's Letter* 2007;23(11):231113.
- 9) Hunt R, Fallone C, Veldhuyzen van Zanten S, et al. Canadian Helicobacter Study Group Consensus Conference: Update on the management of Helicobacter pylori – An evidence-based evaluation of six topics relevant to clinical outcomes in patients evaluated for H pylori infection. *Can J Gastroenterol* 2004;18:547-554.
- 10) ICSI Health Care Guideline: Initial Management of Dyspepsia and GERD. 2006. Available at: http://www.icsi.org/dyspepsia_gerd/dyspepsia_9.html
- 11) Laine L, Hunt R, El-Zimaity H, et al. Bismuth-based quadruple therapy using a single capsule of bismuth biscaltrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. *Am J Gastroenterol* 2003;98:562-7.
- 12) Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. *Gut* 2007;56:772-81.

- 13) National Institute for Clinical Excellence. Clinical Guideline 17 Dyspepsia: management of dyspepsia in adults in primary care. Issue date: Aug 2004. Available <http://www.nice.org.uk/nicemedia/pdf/CG017NICEguideline.pdf>.
- 14) New Zealand Guidelines Group (NZGG). Management of dyspepsia and heartburn. Wellington (NZ): New Zealand Guidelines Group (NZGG); 2004.
- 15) (NHS) National Health Services – Guidelines on the treatment of Helicobacter Pylori – 2nd Revision. Available at: http://www.formulary.chnhs.uk/pdf_doc_files_etc/MMC/040_Helicobacter_Pylori_2nd_Edn.pdf
- 16) RxFiles. H.Pylori Eradication Drug Chart. October 2009. Available at: www.Rxfiles.ca
- 17) Saskatchewan Drug Information Services, College of Pharmacy and Nutrition, University of Saskatchewan. Pharmacists' Role in *Helicobacter pylori* Eradication. 2005; volume 22. No. 3. Available at: http://www.druginfo.usask.ca/pdf/Hp_newsletter.pdf
- 18) Scottish Intercollegiate Guidelines Network (SIGN). Dyspepsia. A national clinical guideline. Edinburgh (Scotland): Scottish Intercollegiate Guidelines Network (SIGN); 2003 Mar. 27 p. (SIGN publication; no. 68). [<http://www.sign.ac.uk/pdf/sign68.pdf>]
- 19) The Medical Letter Treatment Guidelines. Treatment of Peptic Ulcers and GERD. *Med Lett* 2008;6:55-60.
- 20) Vaira D, Zullo A, Vakil N, et al.; Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial.; *Ann Intern Med*; 2007; Vol. 146; pp. 556-63;
- 21) Zagari et al. Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study. *Gut* 2007;56:475-479.

TRAVELLER'S DIARRHEA

- 1) Anonymous. Drugs for traveler's diarrhea. *Medical Letter on Drugs & Therapeutics* 2008;50:58-9.
- 2) (CCDR, 2005) Canada Communicable Disease Report - Health Canada. Public Health Agency of Canada. Statement on new oral Cholera and travellers' diarrhea vaccination. Available: <http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/05vol31/asc-dcc-7/index-eng.php>
- 3) (CDC, 2008) Centers for Disease Control and Prevention. Yellow Book 2008 Chapter 4. Traveler's Diarrhea. Available at: <http://www.cdc.gov/travel/yellowBookCh4-Diarrhea.aspx>.
- 4) De Bruyn G, Hahn S, Borwick A. Antibiotic treatment for travellers' diarrhoea. (Cochrane Review). In: The Cochrane Library, Issue 3, 2000.
- 5) DuPont HL. Systematic review: the epidemiology and clinical features of travellers' diarrhoea. *Aliment Pharmacol Ther.* 2009 Aug;30(3):187-96.
- 6) DuPont HL. Systematic review: prevention of travellers' diarrhoea. *Aliment Pharmacol Ther.* 2008 May;27(9):741-51.
- 7) DuPont HL. Travellers diarrhea: contemporary approaches to therapy and prevention. *Drugs* 2006;66:303-14.
- 8) Hill DR, Ericsson CD, Pearson RD, et al. Infectious Diseases Society of America. The practice of travel medicine: guidelines by the Infectious Diseases Society of America. *Clin Infect Dis* 2006;43:1499-539.
- 9) Hill DR, Ryan T. Management of travellers' diarrhoea. *BMJ* 2008;337:863-7.
- 10) House HR, Ehlers JP. Travel-related infections. *Emerg Med Clin N Am* 2008;26:499-516.
- 11) Jelinek T, Kollaritsch H. Vaccination with Dukoral against travelers' diarrhea (ETEC) and cholera. *Expert Rev Vaccines.* 2008 Jul;7(5):561-7.
- 12) McFarland LV. Meta-analysis of probiotics for the prevention of traveler's diarrhea. *Travel Medicine and Infectious Disease* 2007;5:97-105.
- 13) (NACI) National Advisory Committee on Immunization. *Canadian Immunization Guide*. 7th edition. Ottawa (ON): Public Health Agency of Canada; 2006. Available from: http://www.phac-aspc.gc.ca/publicat/cig-gci/pdf/cig-gci-2006_e.pdf.
- 14) (CATMAT) Committee to Advise on Tropical Medicine and Travel. An Advisory Committee Statement (ACS) on travellers' diarrhea. *Can Commun Dis Rep* 2001;27:1-12.
- 15) Riddle MS, Arnold S, Tribble DR. Effect of adjunctive loperamide in combination with antibiotics on treatment outcomes in traveler's diarrhea: a systematic review and meta-analysis. *Clinical Infectious Diseases* 2008;47:1007-14.
- 16) Sazawal S, Hiremath G, Dhingra U, et al. Efficacy of probiotics in prevention of acute diarrhoea. A meta-analysis of masked, randomized, placebo-controlled trials. *Lancet Infect Dis* 2006;6:374-82.
- 17) Tham J, Odenholt I, Walder M, Brolund A, Ahl J, Melander E. Extended-spectrum beta-lactamase-producing *Escherichia coli* in patients with travellers' diarrhoea. *Scand J Infect Dis.* 2010 Feb 3.
- 18) Vancocin Product Monograph. 2007.

19) Yates J. Traveler's diarrhea. *Am Fam Physician* 2005;71:2095-100.

COMMUNITY ACQUIRED *C. DIFFICILE* ASSOCIATED INFECTION

- 1) Bartlett G. New antimicrobial agents for patients with *Clostridium difficile* Infections. *Current Infectious Disease Reports*. 2009. 11: 21-28.
- 2) Bricker E, Garg R, Nelson R et al. Antibiotic treatment for *Clostridium-difficile* associated diarrhea in adults. *Cochrane Database of Systematic Reviews* 2005; volume 2.
- 3) Cloud J, Kelly CP. Update on *Clostridium difficile* associated disease. *Curr Opin Gastroenterol*. 2007;23(1):4-9.
- 4) Dendukuri N, Costa V, McGregor M, Brophy JM. Probiotic therapy for the prevention and treatment of *Clostridium difficile*-associated diarrhea: a systematic review. *CMAJ*. 2005;173(2):167-70.
- 5) Hawboldt J.C. *difficile*-associated diarrhea: what can you do? *Pharmacy Practice*. 2005;21(5):27-34.
- 6) Hirschhorn LR et al. Epidemiology of community-acquired *Clostridium difficile*-associated diarrhea. *J Infect Dis* 1994;169:127-33.
- 7) Huang H, Nord CE. Can Metronidazole still be used for treatment of *Clostridium difficile* Infections? *Current Infectious Disease Reports*. 2009. 11: 3-6.
- 8) Hyland M et al. *Clostridium difficile*-associated diarrhea in Canada: the results of the Can Nosocomial Infection Surveillance Program (CNISP) 1997 N-CDAD prevalence surveillance project. *Can J Infect Dis* 2001;12:81-8.
- 9) Johnston BL, Conly JM. *Clostridium difficile*: The evolving story. *Can J Infect Dis Med Microbiol*. 2009; 20: 341-345.
- 10) Levy DG et al. Antibiotics and *Clostridium difficile* diarrhea in the ambulatory care setting. *Clin Ther* 2000;22:91-102.
- 11) Malnick S, Zimhony O. Treatment of *Clostridium difficile*-associated diarrhea. *Ann Pharmacother* 2002; 36: 1767-75.
- 12) McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic-associated diarrhea and the treatment of *Clostridium difficile* disease. *Am J Gastroenterol*. 2006;101(4):812-22.
- 13) Nelson R. Antibiotic treatment for *Clostridium difficile*-associated diarrhea in adults. *Cochrane Database Syst Rev*. 2007 Jul 18;(3):CD004610.
- 14) Olmos M, Berenstein EG, Ortiz Z. Cochrane inflammatory bowel disease and functional bowel disorders group. Probiotics for the prevention of *Clostridium difficile* associated diarrhea in adults. *Cochrane Database Syst Rev*;4. 2007.
- 15) Pepin J, Valiquette L, Gagnon S, et al. Outcomes of *Clostridium difficile*-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. *Am J Gastroenterol*. 2007;102(12):2781-8. Epub 2007.
- 16) Pillai A, Nelson R. Probiotics for treatment of *Clostridium difficile*-associated colitis in adults. *Cochrane Database Syst Rev*. 2008; 23(1):CD004611.
- 17) Poutanen S, Simor A. *Clostridium difficile*-associated diarrhea in adults. *CMAJ* 2004; 171(1): 51-8.
- 18) Schroeder MS. *Clostridium difficile*-associated diarrhea. *Am Fam Phys* 2005;71(5):921-8.
- 19) (SHEA-IDSA) Cohen SH, Gerding DN, Johnson S et al. Clinical practice guidelines for *Clostridium difficile* Infection in adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). *Infect Control Hosp Epidemiol*. 2010;31(%):431-455.
- 20) Shen EP, Surawicz CM. The changing face of *Clostridium difficile*. what treatment options remain? *Am J Gastroenterol*. 2007;102(12):2789-92.
- 21) Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent *Clostridium difficile* disease: use of high-dose vancomycin combined with *Saccharomyces boulardii*. *Clin Infect Dis*. 2000 ;31(4):1012-7. Epub 2000 Oct. Surowiec D, Kuyumjian AG, Wynd MA, Cicogna CE. Past, present, and future therapies for *Clostridium difficile*-associated disease. *Ann Pharmacother*. 2006;40(12):2155-63. Epub 2006.
- 22) Rupnik M, Wilcox MH, Gerding DN. *Clostridium difficile* infection: new developments in epidemiology and pathogenesis. *Nat Rev Microbiol* 2009;7(7):526-36.
- 23) Teasley DG, Gerding DN, Olson MM et al. Prospective randomized trial of metronidazole versus vancomycin for *Clostridium-difficile* associated diarrhea and colitis. *Lancet* 1983;2:1043-6.
- 24) Wenisch C, Parschalk B, Hasenhundl M et al. Comparison of vancomycin, metronidazole, and fusidic acid for the treatment of *Clostridium-difficile* associated diarrhea. *Clin Infect Dis* 1996; 22:813-8.

PROPHYLAXIS

MALARIA PROPHYLAXIS

- 1) American Academy of Pediatrics (2006). Malaria. In LK Pickering et al., eds., Red Book: 2006 Report of the Committee on Infectious Diseases, 27th ed., pp. 435–441. Elk Grove Village, IL: American Academy of Pediatrics.
- 2) Boggild AK, Parise ME, Lewis LS et al. Atovaquone-proguanil: report from the CDC expert meeting on malaria chemoprophylaxis (II). *Am J Trop Med Hyg* 2007;76(2):208-223.
- 3) (CDC, 2008) Centers for Disease Control and Prevention. CDC Health Information for International Travel. 2008. (Chapter 4: Malaria). Available at: <http://www.cdc.gov/travel/yellowBookCh4-Malaria.aspx>
- 4) CATMAT 2009. Canadian Recommendations for the Prevention and Treatment of Malaria Among International Travellers 2009. *Can Commun Dis Rep* /2009;35(S1):1-62. Available at: <http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/09vol35/35s1/index-eng.php>
- 5) Chen LH, Keystone JS. New strategies for the prevention of malaria in travelers. *Infect Dis Clin North Am* 2005;19(1):185-210.
- 6) Chen LH, Wilson ME, Schlagenhauf P. Prevention of malaria in long-term travelers. *JAMA* 2006;296(18):2234-44.
- 7) Chiodini P, Hill D, Laloo D, et al. Guidelines for malaria prevention in travellers from the United Kingdom. London, Health Protection Agency, January 2007. <http://www.hpa.org.uk/>
- 8) Croft AM (2006). Malaria: Prevention in travellers. *Clinical Evidence* (15): 1088–1106.
- 9) Freedman DO. Malaria Prevention in Short-Term Travelers. *N Engl J Med* 2008;359:603-12.
- 10) Hill DR, Ericsson CD, Pearson RD, et al. The Practice of Travel Medicine: Guidelines by the Infectious Diseases Society of America. *CID* 2006;43:1499-539.
- 11) Laloo DG, Hill DR. Preventing malaria in travelers. *BMJ* 2008;336:1362-6.
- 12) Public Health Agency of Canada. Malaria – Frequently Asked Questions, Nov 2004. Available at: http://www.phac-aspc.gc.ca/media/advisories_avis/mal_faq-eng.php.
- 13) Suh KN, et al. (2004). Malaria. *Canadian Medical Association Journal*, 170(11): 1693–1702.
- 14) (WHO, 2008) World Health Organization. International Travel and Health. Geneva: WHO, 2008 (Chapter 7: Malaria). Available at: http://www.who.int/ith/chapter_7_2008.pdf.
- 15) Wobeser WL, Keystone JS. Infectious diseases: Malaria prevention. 2009 In eCPS online edition. Canadian Pharmacists Association. Compendium of Pharmaceutical Specialties: [www-e-therapeutics.ca](http://www.e-therapeutics.ca)

PREVENTION OF INFECTIVE ENDOCARDITIS

- 1) Gould FK, Elliott TSJ, Foweraker J et al. Guidelines for the prevention of endocarditis: report of the Working Party of the British Society for Antimicrobial Chemotherapy. *Journal of Antimicrobial Chemotherapy* 2006;57: 1035-42.
- 2) NICE Short Clinical Guidelines Technical Team (2008) Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures. London: National Institute for Health and Clinical Excellence. Available at: <http://www.nice.org.uk>.
- 3) Sroussi HY, Prabhu AR, Epstein JB. Which antibiotic prophylaxis guidelines for infective endocarditis should Canadian dentists follow? *JCDA* 2007;73:401-405. Available at: <http://www.cda-adc.ca/>.
- 4) Wilson W, Taubert K, Gewitz M et al. Prevention of Infective Endocarditis. Guidelines from the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. *Circulation* 2007;116: 1736-54.

APPENDICES

EXTENDED FREQUENCY AMINOGLYCOSIDE DOSING METHOD

- 1) Anaizi N. Once-daily dosing of aminoglycosides. A consensus document. *International Journal of Clinical Pharmacology & Therapeutics*. 1997;35:223-6.

- 2) Baily TC, Little JR, Littenberg B, et al. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. *Clin Infect Dis* 1997;24:786-795.
- 3) Ferriols-Lisart and Alos-Alminana. Effectiveness and safety of once-daily aminoglycosides: a meta-analysis. *Am J Health-Syst Pharm*.1996; 53:1141-50.
- 4) Freeman C et al. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice, *Journal of Antimicrobial Chemotherapy* 1997; 39, 677-686.
- 5) Munckhof WJ, Grayson ML, Turnidge JD. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. *J Antimicrob Chemother* 1996;37:645-663
- 6) Nicolau DP, Freeman CD, Belliveau PP et al. Experience with a once-daily aminoglycoside program administered to 2184 adult patients. *Antimicrob Agents Chemother* 1995; 39:650-655.
- 7) Schumock GT, Raber SR, Crawford SY, et al. National Survey of Once-Daily Dosing of Aminoglycoside Antibiotics. *Pharmacotherapy* 1995; 15:201-209.
- 8) Traynor AM, Nafziger AN, Bertino JS, Jr. Aminoglycoside dosing weight correction factors for patients of various body sizes. *Antimicrob Agents Chemother* 1995;39:545-8.
- 9) Urban A, Craig W. Daily dosage of aminoglycosides. *Curr Clin Top Infect Dis* 1999;17:236-255.